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Abstract 
Background: Significant concerns are associated with the use of broad-spectrum antibacterial agents, 
including collateral eradication of beneficial bacteria from the human microbiome, the onset of 
antibacterial-associated infections, and continued emergence of antibacterial drug resistance. As such, a 
critical need for novel and selective antibacterial targets exists. The investigation of two such targets, 
each pertaining to the highly concerning infections caused by streptococcal species and Clostridioides 
difficile, are presented herein. Bacterial topoisomerase I represents a potentially promising narrow-
spectrum target as studies have arisen demonstrating its essentiality in bacterial species lacking the only 
other type IA topoisomerase (topoisomerase III). Additionally, recent studies demonstrating the 
essentiality of the fabK gene expressing enoyl-ACP reductase II (FabK) in C. difficile indicate its significant 
potential as a narrow-spectrum target. Presented here are data characterizing and validating both the 
TopoI and FabK enzymes as novel antibacterial targets via the implementation of an array of drug 
discovery techniques, including structural studies, biochemical assay development and application, and 
inhibitor screening and testing. Methods: An assortment of drug discovery techniques were employed for 
the targeting of SmTopoI and CdFabK, including different protein expression and purification techniques; 
X-ray crystallography; various biophysical and biochemical techniques for target characterization, 
validation, and drug screening; and different lead development and optimization studies. Results: The 
respective genes for SmTopoI and CdFabK have been cloned, and the expression and purification of 
various constructs of each target have been carried out and optimized for further analysis. The crystal 
structure of SmTopoI_N65 has been determined to 2.06 Å and diffracting CdFabK crystals (3.5 Å) have 
been attained. A high-throughput plate-based biochemical fluorescence kinetic assay has been optimized 
for screening against the CdFabK enzyme. Furthermore, activity and modality of inhibition assessment of 
small-molecule inhibitors of the CdFabK enzyme have been conducted, including phenylimidazole and 
benzothiazole compounds. Phenylimidazole analogues have been found to display micromolar inhibitory 
activity against CdFabK, and a benzothiazole analogue has been found to display nanomolar inhibitory 
activity against the target. Conclusions: The SmTopoI and CdFabK enzymes present potentially novel, 
narrow- spectrum antibacterial drug targets, and substantial progress has been made toward the rational 
targeting of these two enzymes. Of particular note, the first structure of a Topo I fragment from a gram-
positive organism, S. mutans, has been determined. Enzymology and inhibitor studies have been 
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Background: Significant concerns are associated with the use of broad-spectrum 
antibacterial agents, including collateral eradication of beneficial bacteria from the 
human microbiome, the onset of antibacterial-associated infections, and continued 
emergence of antibacterial drug resistance. As such, a critical need for novel and 
selective antibacterial targets exists. The investigation of two such targets, each 
pertaining to the highly concerning infections caused by streptococcal species and 
Clostridioides difficile, are presented herein. Bacterial topoisomerase I represents a 
potentially promising narrow-spectrum target as studies have arisen demonstrating its 
essentiality in bacterial species lacking the only other type IA topoisomerase 
(topoisomerase III). Additionally, recent studies demonstrating the essentiality of the 
fabK gene expressing enoyl-ACP reductase II (FabK) in C. difficile indicate its 
significant potential as a narrow-spectrum target. Presented here are data characterizing 
and validating both the TopoI and FabK enzymes as novel antibacterial targets via the 
implementation of an array of drug discovery techniques, including structural studies, 
biochemical assay development and application, and inhibitor screening and testing. 
 
Methods: An assortment of drug discovery techniques were employed for the targeting 
of SmTopoI and CdFabK, including different protein expression and purification 
techniques; X-ray crystallography; various biophysical and biochemical techniques for 
target characterization, validation, and drug screening; and different lead development 
and optimization studies.  
 
Results: The respective genes for SmTopoI and CdFabK have been cloned, and the 
expression and purification of various constructs of each target have been carried out and 
optimized for further analysis. The crystal structure of SmTopoI_N65 has been 
determined to 2.06 Å and diffracting CdFabK crystals (3.5 Å) have been attained. A 
high-throughput plate-based biochemical fluorescence kinetic assay has been optimized 
for screening against the CdFabK enzyme. Furthermore, activity and modality of 
inhibition assessment of small-molecule inhibitors of the CdFabK enzyme have been 
conducted, including phenylimidazole and benzothiazole compounds. Phenylimidazole 
analogues have been found to display micromolar inhibitory activity against CdFabK, 
and a benzothiazole analogue has been found to display nanomolar inhibitory activity 
against the target. 
 
Conclusions: The SmTopoI and CdFabK enzymes present potentially novel, narrow-
spectrum antibacterial drug targets, and substantial progress has been made toward the 
rational targeting of these two enzymes. Of particular note, the first structure of a Topo I 
fragment from a gram-positive organism, S. mutans, has been determined. Enzymology 
and inhibitor studies have been conducted supporting the druggability of CdFabK and 
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 The current threat of antibacterial resistance looms large across the entire globe. 
Only a century ago, the threat posed by bacterial infections seemed all but defeated. As 
initial antibacterial breakthroughs were made, humanity’s victory over such infections 
was generally regarded as a near guarantee. As resistance mechanisms surfaced, however, 
pathogenic bacterial infections crept their way back into the healthcare arena, regaining 
an insidious foothold that, in retrospect, now appears to have been underestimated. 
Resistances continued to evolve, outpacing novel and effective antibacterial drug 
development and cutting into the hard-won gains humanity had made. Eventually, easily 
treated infections again became dire and the world is once more on alert, demonstrating 
the significant need for a modern and concerted effort to develop novel antibacterial 
agents. A compelling modern argument is being made that such an effort should include, 
at least in part, an investigation of narrow-spectrum targets for the development of these 
much needed novel antibacterial agents. A brief survey of the historic eras, modern 
efforts, and possible future of antibacterial drug discovery may act as a road map for such 
a case. Furthermore, a discussion of the requirements such narrow spectrum 
investigations entail helps to accurately present the accompanying benefits and costs. 
 
 
Antibacterial Drug Discovery Eras: Past, Present, and Future 
 
The Golden Era   
 
Before the advent of antibacterial drugs, any insult small or large that introduced 
the risk of infection was potentially fatal. From a sliver to surgery to simply being in 
close proximity to a person suffering from a communicable disease, the ever-looming 
threat of infectious disease was everywhere. However, in the early 1900s, an 
unprecedented breakthrough occurred. In 1928, Alexander Fleming made his famously 
“serendipitous” discovery of penicillin, and the “golden era” of antibacterial discovery 
was born (Figure 1-1).1 During this era, phenotypic whole-cell natural product screening 
predominated, bringing with it a prosperity in antibacterial drug discovery research yet to 
be rivaled. The majority of antibacterial agents arose from this era, including the 
penicillins, sulfonamides, vancomycin, streptomycin, chloramphenicol, tetracycline, and 
erythromycin. In fact, many of these antibiotics, or their derivatives, are still in use and 




                                                 
 
1 Adapted from final submission by permission of The Royal Society of Chemistry. Jones, J. A., Virga, K. 
G., Gumina, G. & Hevener, K. E. Recent Advances in the Rational Design and Optimization of 





Figure 1-1. Antibacterial eras and recent advances. 
 
Long past the historical “golden era” of antibacterial drug discovery, the modern 
“resistance era” is being countered by new legislation and advances in the rational design 
of antibacterial agents.  
Reprinted from final submission by permission of The Royal Society of Chemistry. 
Jones, J. A., Virga, K. G., Gumina, G. & Hevener, K. E. Recent Advances in the Rational 






The Medicinal Chemistry Era  
 
An effective follow-up to this preeminent era occurred in the mid- to late-
twentieth century in the form of the formidable “medicinal chemistry era.” Born out of 
the golden era, the medicinal chemistry era forsook the phenotypic screening modalities 
that preceded it and instead shifted researchers’ focus toward an elegant combination of 
synthetic modifications of previously discovered compounds, high-throughput screening, 
and prototypical library design.2 Antibacterial agents discovered or developed during this 
era include ampicillin, methicillin, the cephalosporins, and the quinolones. While early 
hope and expectations at the time were that this era would usher in a veritable end to the 
long reign of bacterial infections, history would more realistically highlight it as an 
incognizant precursor to the modern “resistance era”—an age marked by the menace of 
expanding bacterial resistance coupled with the unfavorable reality of an inversely 
diminishing antibacterial pipeline.3  
 
The Resistance Era  
 
In stark comparison to the gains made against bacterial infections during the 
historical golden and medicinal chemistry eras, the contemporary resistance era is 
overshadowed by a resurgence of infections for which modern antibacterials are less or 
altogether ineffective, such as the “ESKAPE” pathogens (Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas 
aeruginosa, and Enterobacteriaceae species). Moreover, the current drug discovery 
climate is noticeably less fruitful than that of its forerunners, due in part to the fact that it 
is geared around more arduous and time-consuming rational drug design modalities that 
highlight target-based high throughput screening (HTS) campaigns while implementing 
comparatively exhaustive and limited tools like combinatorial libraries.4 The few 
antibacterial agents developed during this era include linezolid and daptomycin. Apart 
from relatively slower process inherent to rational drug design and discovery, additional 
issues are associated with contemporary efforts that were, for the most part, innately 
avoided in the past by the very nature of the phenotypic whole-cell screening methods 
used in the golden era include difficulties with inadequate cell penetration, drug efflux, 
and in vivo instability, to name a few. Overall, the relatively reduced output of the 
modern drug discovery era combined with the accelerating occurrence of antibacterial 
drug resistance and the rapid rate at which infections spread with modern travel has 
merged to form an alarming modern public health concern with an even more concerning 
prognosis of the future.  
 
The Post-Antibiotic Era  
 
Looking ahead on the antibacterial timeline, the next major antibacterial drug 
discovery era is commonly forecasted as the “post-antibiotic era,” which foretells the 
existence of a bleak period reminiscent of the time before the existence of antibacterial 
agents—a future in which human deaths attributed to resistant microorganisms rises from 
the current 700,000 per year to an excess of 10 million per year.2 The United Nations 
(UN) World Health Organization (WHO) Ad hoc Interagency Coordination Group on 
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Antimicrobial Resistance (IACG) reported this year (2019) that by 2050, drug-resistant 
microbial diseases could cause economic damage on par to the 2008-2009 global 
financial crisis, and that by 2030, up to 24 million people could be forced into extreme 
poverty due simply to the effects of antimicrobial resistance.5 In order to adequately 
combat this threat, a multi-faceted approach has commenced. Both public and private 
entities across the globe have risen to meet the challenge of antimicrobial resistance in an 
effort to avert the post-antibiotic era, including new legislative and research efforts.  
 
 
Public and Private Responses to the Threat of Antimicrobial Resistance 
 
Within the last several years of the “resistance era,” the United States has 
launched several initiatives aimed at curbing the threat of infectious diseases including 
legislation like the Generating Antibiotics Incentives Now Act (GAIN Act) aimed at fast-
tracking the development and approval of Qualified Infectious Disease Products (QIDPs). 
Likewise, Europe has recently implemented its own similar responses, such as the 
Innovative Medicines Initiative (IMI) ENABLE project under the “New Drugs 4 Bad 
Bugs” (ND4BB) program aimed specifically at battling Gram-negative bacteria. The 
WHO has also led multiple initiatives aimed at addressing antibacterial awareness, 
including the launch of World Antibiotic Awareness Week, the Global Antimicrobial 
Resistance Surveillance System (GLASS), the Global Antibiotic Research and 
Development Partnership (GARDP), as well as the formation of the aforementioned 
IACG. However, while momentum has increased, these governmental responses did not 
manifest themselves spontaneously. In large part, they were the result of long-fought 
battles by private citizens and associations working diligently to assess, interpret, and 
raise the alarm regarding the overall problem—parts of an overall war still being fought. 
 
Appropriately combatting the modern threat of microbial disease centers around 
countering antibacterial resistance. Therefore, it is arguable that the individuals best 
suited to assess the threat are infectious disease-focused healthcare professionals 
themselves. Indeed, an early leader in this fight, the Infectious Disease Society of 
America (IDSA) has gone to great lengths to increase public awareness of the looming 
problem. As early as 2002, IDSA publicly conveyed worry for the lack of noteworthy 
research and development (R&D) aimed at combatting multidrug resistant (MDR) 
microbial infections.6 By 2004, IDSA had issued a clarion call to government agencies 
for the enactment of formal regulatory and funding initiatives to aid in the fight against 
the forthcoming antibacterial resistance crisis.7  Moreover, in 2010, IDSA introduced its 
“10 x ‘20 Initiative” calling for R&D sufficient to bring 10 novel and effective systemic 
antibacterial agents by the year 2020.8 By 2013, an update by the IDSA communicated 
some advancement had been made, but that it still appeared inadequate to properly 
confront the growing problem of resistance.9  
 
That same year, the Centers for Disease Control and Prevention (CDC) appeared 
to take the regulatory lead when it released its report titled “Antibiotic resistance threats 
in the United States, 2013.”10 In the report, the CDC called out four “core actions” to 
prevent antibiotic resistance, which included preventing the spread of infections and, 
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therefore, the spread of resistance; tracking antibiotic resistant infections; improving 
antibiotic prescribing via effective stewardship; and lastly, developing new diagnostic 
tests and new drugs. Because the natural evolution of bacteria includes antibiotic 
resistance, the CDC notes, the threat can be slowed with adequate measures, but never 
completely avoided or suspended entirely. This concept has been showcased recently by 
the existence and conservation of various elements of bacterial resistomes from isolated 
cave bacteria previously unexposed to modern antibacterial drugs.11 Because of this 




Recent Advances in Antibacterial Drug Discovery, the Modern Era 
  
Attempts to address the modern challenge of antibacterial drug discovery have 
taken place via several different avenues. Since the 1980s, FDA approvals of new 
antibacterial agents steadily declined from sixteen approvals between 1983 and 1987 to 
only two approvals between 2011 and 2012, then rebounded between 2013 and 2017, 
increasing to seven approvals during that period.6 First glance suggests that private and 
public initiatives have begun to have a positive effect, resulting in a recent upswing in 
antibacterial drug discovery efforts. However, with the exception of an extremely small 
number of antibacterial agents possessing a novel mechanism of action (MOA), modern 
research efforts have primarily focused on the optimization of known antibacterial agents 
emphasizing rational design strategies geared around classic, conventional targets 1,6 
(Table 1-1). For the most part, the substantial bulk of these targets are well validated and 
have a long history of practical exploitation.4 In general, these modern antibacterial 
efforts have revolved around improving or regaining overall spectra of activity of the 
agents, as well as improving physicochemical properties, pharmacokinetics, adverse 
effects, off-site activities, and so on. In these efforts, modern antibacterial researchers 
have recently begun to “re-discover” natural products chemistry, complementing their 
endeavors with contemporary approaches like rational semi-synthetic modifications.12,13  
 
Recent advances in the rational design and optimization of antibacterial agents 
include the development of various agents across multiple drug classes. Developmental 
status of these novel agents range from early-stage clinical trials to recent approval by the 
U.S. Food and Drug Administration (FDA) while, unfortunately, some hopeful products 
have recently been withdrawn altogether.1 A brief summary of recently developed (within 
the last decade), mostly small molecule antibacterial agents is as follows:  
 
Advanced generation cephalosporins   
 
Recent advances in the chemistry of the β-lactam antibiotics have resulted in the 
approval and late-stage development of several advanced (or 5th) generation 
cephalosporins that boast enhanced spectra of activity (SOA), including activity against 
some Extended-Spectrum ß-Lactamase (ESBL) producers, methicillin-resistant  
Staphylococcus aureus (MRSA), and Pseudomonas aeruginosa (PA). There are currently  
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Table 1-1. Continued. 
 
 
Does not include “novel” combination products comprised of multiple non-novel agents.  
DHFR, dihydrofolate reductase; LPS, lipopolysaccharide; MOA, mechanism of action; NDA, new drug application; FAS-II, bacterial 
fatty acid biosynthesis pathway. 
Data sources: Jones, J. A., Virga, K. G., Gumina, G. & Hevener, K. E. Recent Advances in the Rational Design and Optimization of 
Antibacterial Agents. Medchemcomm 7, 1694-1715, https://doi.org/10.1039/C6MD00232C (2016).1 
Talbot, G. H. et al. The Infectious Diseases Society of America's 10 x '20 Initiative (Ten New Systemic Antibacterial Agents FDA-
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two next generation cephalosporins that were recently approved and two in late-stage 
development (Phase 2 or Phase 3) in the U.S.6  
 
Next generation beta lactamase inhibitors  
 
The development of two new classes of ß-lactamase inhibitors (BLIs) has resulted 
in a much-needed respite from the steadily increasing threat of multi-drug resistant 
(MDR) and pan-drug resistant bacterial infections. There are currently eight novel BLIs 
of note, with four recently approved or in late-stage development, and four more in early 
stage development (Phase 1).6 
 
Next generation oxazolidinones  
 
The oxazolidinone class of antibacterials is a fully synthetic class of agents and 
has been considered a major breakthrough in antimicrobial drug development with 
linezolid standing as the best-known representative.14 The recent emergence of linezolid 
resistance has driven the investigation and advancement of next-generation 
oxazolidinones with improved antibacterial activities and decreased adverse effect 
profiles.15-17 To that aim, one novel oxazolidinone has recently been approved, and two 
more are in late-stage development.6 
 
Next generation bacterial topoisomerase inhibitors  
 
Bacterial topoisomerases are extremely well validated as efficacious antibacterial 
drug targets, and the type II topoisomerase inhibitors known as quinolone antibiotics 
have proven to be one of the most practically effective antibacterial classes in recent 
history. Quinolones have shown astonishing popularity over the last several decades, 
perhaps contributing to the sharp rise in use, or overuse, and subsequent respective 
resistance rates across the country.18 Nonetheless, bacterial topoisomerases have gained a 
great deal of attention within the realm of antibacterial drug development, and several 
inhibitors within this class have either been recently approved or are in late-stage clinical 
trials. Additionally, this is one of the few classic targets with new antibacterial agents 
being developed that showcase novel MOAs. One of these classes of new agents, known 
as novel bacterial topoisomerase inhibitors (NBTIs), consequently lack cross-resistance 
among pathogens possessing quinolone resistance. Additionally, the newer 
spiropyrimidinetrione class has recently arisen with yet another unique mechanism of 
topoisomerase II inhibition. Though discovered via whole-cell activity screens, 
spiropyrimidinetriones have since been rationally optimized.19 As one would expect, the 
unique MOIs of these newer classes imply accordingly unique structures, scaffolds, and 
SARs. Overall, two novel bacterial topoisomerase inhibitors have recently been 
approved, and five are in late-stage development. 6 
 
Next generation tetracyclines  
 
Tigecycline (Tygacil®; Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc., 
initial U.S. approval in 2005) is the first semi-synthetic representative of a class of 
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antimicrobials called glycylcyclines.20 The design and synthesis of glycylcyclines were 
intended to overcome the major problems of modern ribosomal protection and efflux-
pump-mediated tetracycline resistance.21,22 The success and utility of tigecycline, coupled 
with climbing resistance rates against other major antibacterial classes, have recently 
prompted the development of several more novel tetracycline analogues, including two 
recently approved agents and one in early stage development.6 
 
Next generation macrolides  
 
Macrolide antibiotics are natural product-based antibacterials composed of a 
large, macrocyclic lactone core, to which a variety of sugar substituents may be attached. 
Disadvantages of the macrolide antibiotics include limited Gram-negative activity, acid 
instability limiting the oral effectiveness of some compounds in the class, and interaction 
with human drug metabolizing enzymes in the cytochrome P-450 system that can result 
in significant drug interactions.23  Further, emerging resistance, typically due to 
alterations of the macrolide binding site on the ribosome, has limited the clinical utility of 
older compounds in the class and, therefore, novel modified ketolide antibacterials have 
been developed to overcome such issues. To date, three novel macrolides are currently in 
late-stage development. 
 
Next generation aminoglycosides  
 
Development of next-generation aminoglycosides has been somewhat limited. 
Nonetheless, semi-synthetic techniques have been implemented to develop a single novel 
aminoglycoside, plazomicin. It has shown activity against a broad range of Gram-positive 
and Gram-negative organisms, including ESBL-producing pathogens, when used in 
combination therapy with other antibacterial agents.24  Plazomicin is not active, however, 
against organisms harboring aminoglycoside resistance due to the expression of 
ribosomal methylases.6,25 It is the sole next-generation aminoglycoside in development, 
and was very recently approved.6 
 
Novel bacterial folate synthesis inhibitor  
 
Iclaprim (Motif Bio, PLC) is the sole next generation dihydrofolate reductase 
(DHFR) inhibitor in late-stage development. It was rationally designed using structural 
data and molecular modeling, and has potent Gram-positive bactericidal activity that 
includes activity against methicillin-sensitive S. aureus (MSSA), MRSA, and 
trimethoprim-resistant F98Y mutant strains.26,27  Activity against Gram-negative and 
atypical organisms is reported to be similar to that of trimethoprim.28 Iclaprim was 
granted qualified infectious disease product (QIDP) status and is in the NDA stage.6 
 
Novel inhibitors of the bacterial FAS-II pathway 
 
Two promising anti-staphylococcal FabI inhibitors are currently under 
development, both of which represent notable rational design methods. The first 
compound, CG400549, was designed to overcome the unfavorable pharmacokinetics of 
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triclosan by replacing a metabolically unstable phenol group with a pyridone ring system 
and the small ether linker with a methylene group.29,30 CG400549 binds to the FabI-
NADPH (reduced cofactor) binary complex, making the drug uncompetitive with respect 
to NADPH binding and competitive with respect to the binding of the FabI enoyl 
substrate.  The other FabI inhibitor in development, afabicin (Debio-1450) was developed 
using a classically iterative, structure-guided strategy, and showcases a unique MOA 
where the agent binds to a binary complex of the enzyme and its oxidized cofactor, 
NADP+.
31-33  Modern structural information has guided recent efforts to expand the 
activity of CG400549 by iterative, structure-guided design strategies, to include Gram-





The lipoglycopeptides contain large lipophilic moieties linked to glycopeptides, 
making their molecular weight notably high and, therefore, inherently separate from 
“small molecule” antibacterials.34 Nonetheless, two lipoglycopeptides with notable 
Gram-positive activity, dalbavancin and oritavancin, were approved within the last five 
years.6 
 
Novel penems  
 
The carbapenems are ß-lactam antibacterials developed several decades ago that 
showed exceptional activity against MDR bacteria.35 Their use has become more limited 
over the years, though, as resistance to the class was observed very soon after their 
clinical emergence.36 Recent development of novel penems has resulted in one agent in 
early stage development and one oral agent in late-stage development.6 
 
Novel monobactam  
 
Monobactams were discovered several decades ago, with the prototype aztreonam 
showcasing, as the class name would indicate, an unfused ß-lactam ring.37 While 
aztreonam is susceptible to serine beta lactamases, the novel monobactam LYS228 shows 
greater stability against SBLs and is currently in late-stage development. 
 
Other novel agents 
 
While more difficult to classify, several other novel antibacterial agenta are 
currently under development. These include the cell wall synthesis inhibitor fosfomycin, 
currently undergoing NDA status; the protein synthesis inhibitor fusidane, known as 
fusidic acid, currently in late-stage development; the pleuromutlin protein synthesis 
inhibitor known as lefamulin, currently in NDA status; the cationic, Gram-negative outer 
membrane targeting potentiator known as SPR741, currently in early-stage development; 
and Murepavadin (POL7080, Polyphor, Ltd.), which is a synthetic beta hairpin 
peptidomimetic with anti-pseudomonal activity currently in late-stage development and 
is, notably, the only novel antibacterial agent with a truly novel target.6,38 It is worth 
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mentioning, however, that as a peptide, this agent is not a small molecule antibacterial, 
per se.  
 
 
The Narrow Spectrum Era 
 
Current techniques and methods being implemented in the rational design and 
optimization of antibacterial agents suggest a subtle change in the recent state of affairs 
regarding the struggle against bacterial infections. As described above, recent advances in 
various techniques have helped gain small amounts of ground in the modern struggle 
against resistant bacterial infections—a conflict where prolonged trends have mostly 
demonstrated losses. Promising standouts include specific chiral configurations of new 
quinolones that grant improved activity under acidic conditions, fully-synthetic 
techniques used in the next-generation tetracyclines that allow for novel side-chains that 
grant activity against resistant pathogens, and semi-synthetic techniques used in the next-
generation macrolides that allow for the modification of functional groups that improve 
binding and, again, activity against resistant pathogens. The recent advances in the 
rational design and optimization of antibacterial agents are both encouraging in the fact 
that the downward trend in FDA approvals has been, if not reversed, at least momentarily 
slowed. Nonetheless, results are also somewhat discouraging in the fact that up until this 
point, all recent approvals lack novel targets. 
 
With newly implemented incentivization and modern advances in research 
methods, it is hoped that the threat of antibacterial resistance will continue to be met with 
appropriate countermeasures. The number of novel antibacterial agents that were recently 
approved or under late-stage development is highly encouraging, as is recent U.S. and 
European legislation facilitating the rapid development and approval of new 
antibacterials. By 2016 alone, there were almost 60 antimicrobial drugs granted QIDP 
status in the U.S., six of which had already attained U.S. approval, and 37 that were in 
late-phase clinical trials. In the last ten years, twelve new antibacterial agents were 
approved and, by 2019, three agents were in NDA status.6 These results stand as evidence 
for the initial success of these new initiatives and their ability to drive the advancement of 
antibacterial development. As mentioned above, however, a thorough analysis of the 
antibacterial pipeline showcases a trend that is still somewhat troubling. While there has 
been a noteworthy increase in antibacterial drug discovery and development, the 
astonishingly low number of compounds under development with original targets 
highlights the urgent need for the characterization and validation of such.  
 
This need for novel, validated targets has been emphasized by numerous reports 
from public health agencies across the world indicating the fact that resistance to 
antibacterial agents that exploit traditional targets continues to surge. Just within the last 
several years, the CDC reported a fatality within the United States resulting from a strain 
of New Delhi metallo-ß-lactamase (NDM) possessing Klebsiella pneumoniae found to be 
resistant to 26 antibiotics, including every aminoglycoside and polymyxin agent tested, 
and possessing what is assumed to be a novel resistance mechanism to the commonly 
regarded “antibiotic of last resort,” colistin.39 Despite encouraging progress being made 
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with optimization strategies, relying on classic antibacterial targets alone is simply not 
enough. It has been argued that ample attention should be turned toward the future 
development of selective antibacterial targets, a move that is expected to bolster the 
antibacterial pipeline as well as slow the development of antibacterial resistance. It is 
reasonable to believe that antibacterial agents geared toward such selective targets would 
have substantial additional benefits—such as the possibility of developing effective 
microbiome-sparing agents and the requirement for rational, more responsible use of 
antibacterial agents that would in turn contribute to greater antibacterial stewardship. This 
is giving way to what some predict will be the next phase of antibacterial discovery and 
development—the “narrow spectrum-era.”2  While indeed an exciting prospect, 
characterizing and validating novel narrow-spectrum targets would of course require an 
understandably substantial amount of intellectual resources, innovation, and effort 
previously unseen—including fully rational drug design based around heretofore novel 
and unconventional targets, the employment of a broad arsenal of drug discovery skills 
and techniques (Figure 1-2), and a certain degree of anticipated success.  
 
 
Requisite Antibacterial Drug Discovery Skills and Techniques 
 
Target identification and production techniques 
 
Techniques involved with preliminary target identification include a thorough 
literature review in order to survey the successes, failures, difficulties, and considerations 
of researchers who may have already pursued similar research paths; genomic 
bioinformatics techniques for data mining the existence of genes of interest for rational 
targets in pathogens of interest, as well as comparative genomic techniques for assessing 
the absence or existence of respective selective or otherwise rational targets in other 
bacteria; other bioinformatic techniques that allow one to assess certain parameters of the 
target that will later prove invaluable during target production, characterization, and 
compound screening—parameters such as target size, stability, isoelectric points, 
extinction coefficient, solubility, and lipophilicity. 
  
Once a satisfactory rational target has been selected that confers a particular 
degree of anticipated success, techniques centered around target production become of 
immediate importance. First, cloning techniques are required to produce the gene of 
interest that codes for the particular target enzyme. First, the gene must be acquired, must 
commonly done by polymerase chain reaction (PCR) amplification. Different cloning 
techniques must then be used to transfer the gene of interest into a suitable expression 
vector. Such cloning techniques include classic restriction enzyme cloning, TOPO 
cloning, TA cloning, Gibson cloning, Gateway cloning, ligation-independent cloning 
(LIC), and others. Decisions regarding codon optimization for anticipated expression 
organisms must also be considered at this point. Alternatively, the gene and an 
appropriate vector may also simply be purchased. As with all research, a cost analysis of 
time, money, manpower, and perhaps learning opportunity must be taken into account 






Figure 1-2. Drug discovery skills and techniques used in the investigation of 





and purification techniques must be considered here, as an appropriate vector must be 
selected that carries the appropriate induction methods to produce the target enzyme, as 
well as the appropriate tags desired for solubility, recognition, purification, etc. Once the 
gene of interest is produced and has been inserted into a satisfactory vector, it must be 
transformed into a production host, such as bacteria (most commonly Escherichia coli), 
yeast, insect, or mammalian cell lines. 
  
Next, protein production techniques become imminently necessary. This includes 
growth and induction techniques, such as classic isopropyl-ß-D-1-thiogalactopyranoside 
(IPTG) induction, tetracycline induction, or autoinduction, among others. Target protein 
can then be harvested and purified via a number of various popular techniques, 
ammonium sulfate precipitation, immobilized metal affinity chromatography (IMAC), 
ion exchange chromatography, hydrophobic interaction chromatography (HIC), and size-
exclusion chromatography (SEC) among some of the most popular. Numerous other 
techniques are available, including more costly, but also highly specific antibody directed 
purification systems. A researcher can also use resins and slurries that apply his or her 
purification modality of choice under gravity filtration, or choose pre-packed columns 
and fast protein liquid chromatography (FPLC) systems for higher throughput and 
convenience. and expertise in protein biochemistry and purification make it possible to 
tailor the purification protocol to the characteristics and needs specific to a particular 
rational target. Upon determination of a rational antibacterial target and its subsequent 
procurement, it should be immediately and fully engaged. While multiple steps exist 
during such engagement, it is somewhat difficult to list a definitive order for proper 
execution of such and, therefore, a certain degree of adaptability is required. Nonetheless, 
the techniques essential for further pursuit follow, but are not in a definitive order and, 
instead, all have the potential to contribute a portion of all knowledge required for 
successful rational antibacterial drug discovery and development. 
 
Preliminary target characterization 
 
While every protein is different, some targets may be inherently stable and 
immediately easy to work with, while others prove recalcitrant to many conditions and 
procedures from the moment they are purified. Such intractability may prove not only 
inconvenient, but altogether discordant with the timeline a research team is under. 
Therefore, it is of the utmost benefit to characterize the target protein, and any constructs 
created, as soon as possible in order to move forward as efficiently as possible. As such, a 
number of techniques exist to aid in such hasty pursuits.  
 
General techniques. Several miscellaneous techniques exist for the preliminary 
characterization of a purified target protein that may be of some service to a research 
team. While much information can be determined about the protein of interest from the 
aforementioned application of bioinformatics and literature searches, techniques exist to 
corroborate calculated protein parameters or, often times, determine a characteristic more 
precisely. Examples include, but are not limited to, isoelectric focusing to determine a 
precise isoelectric point that could prove highly useful during stability assessments; 
denatured or native polyacrylamide gel electrophoresis (PAGE) for determining sample 
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purity, analyzing degradation, or evaluating dimerization; analytical gel filtration 
chromatography, or analytical SEC, for analyzing purity, size, dimerization, and other 
global characteristics of a target protein, such as whether or not it is retaining a bound 
cofactor or not; and mass spectrometry (MS), which offers an enormous amount of 
knowledge about the target, from identification via peptide fingerprinting, to de novo 
sequencing of an unknown target, to general structural inferences, to protein-protein 
interaction analyses via cross-linking MS.40,41 While only a few examples of general 
preliminary techniques, these highlight the importance of possessing a thorough working 
knowledge of protein biochemistry and the tools available for one’s use in thoroughly 
analyzing and characterizing a target protein in early-stage antibacterial drug discovery. 
 
Thermal shift assay. Another popular and very useful early-stage target 
characterization technique resides in the thermal shift assay, or differential scanning 
fluorimetry (DSF). This technique should be employed as early as possible as it may 
allow for subsequent analyses to occur that, without stable target protein, may not be 
feasible. Mastery of this technique is actually dually beneficial, as it can be used to 
identify ligands that bind to the purified target enzyme, thereby stabilizing the protein and 
increasing its melting temperature—which is determined by a hydrophobic fluorescent 
dye binding to the similarly hydrophobic innards of the target protein that are exposed 
upon melting and resulting in a measurable increase in fluorescence—or it can simply be 
used to identify salt, polyol, buffer, pH, or additive conditions that stabilize the protein, 
making further work notably easier.42   
 
Compound screening and hit selection techniques 
 
After purified stable, homogenous target protein is acquired, one of the next 
rational drug discovery steps is compound screening and selection of hit compounds for 
the sake of assessing how “druggable” the target is—meaning how likely is it that the 
target is accessible to a small molecule that can elicit a measurable biological response of 
biological and, potentially, clinical import. Once again, an immediately initial technique 
worthy of noting with respect to compound screening and hit selection is simply a 
thorough literature review.  
 
Active compound literature review. During early screening, it may be possible to 
find previous hits or compounds discovered or developed previously against related or 
otherwise similar targets by other research groups that may also be active against a novel 
rational target of interest. Even if such a compound does not show similar activity against 
the new target, it may prove useful as a chemical probe with utility later on in target and 
hit validation and characterization, or as a scaffold for iterative lead development and 
structure-activity relationship (SAR) analyses. Whether or not such an asset may be 
exhumed from the literature for any given rational drug discovery campaign, a battery of 
other useful drug discovery techniques prove to be absolute necessities.  
 
Biophysical techniques. For truly novel antibacterial targets, previous inhibitors 
or chemical probes simply may not be known, or may not even exist. What is more, high-
throughput screening (HTS) assays may not be developed, either. Also, knowledge of 
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conditions necessary for the stabilization of the targeted protein may not be immediately 
available. Nonetheless, a reasonable starting point in the search for useful chemical 
probes may be found in a more medium throughput method, or even a low throughput 
method under the most dire of circumstances.  
 
As mentioned above, the thermal shift assay technique is of significant utility 
during early stages of antibacterial drug discovery for the sake of preliminary protein 
characterization. While extremely useful for identifying stabilizing conditions for the 
novel target, the utility of the thermal shift assay in finding ligands that bind the enzyme 
is also substantial, but must be pursued cautiously. The reason for this is that just because 
a compound is discovered that binds the enzyme as a ligand, and therefore shifts the 
melting temperature higher, does not guarantee it has any activity, such as agonism or 
antagonism. As such, the discovery of such a compound would unquestionably call for 
further analysis and highlights the need for the use of a known functional assay or, if the 
existence for such does not exist, the requisite development of such. 
 
Lower throughput techniques used for the study of ligand-protein binding 
interactions include surface plasmon resonance (SPR; low to medium throughput) and 
isothermal titration calorimetry (ITC; lowest throughput of methods discussed). SPR 
requires the first protein binding component be immobilized on a sensor chip as the other 
test-compound binding component is free in solution and passed over the first component 
while subtle differences in refractive index are detected at the surface of the sensor.43 
ITC, on the other hand, simply uses heat as a signal to quantitatively measure binding 
affinity (Ka), stoichiometry (n), and enthalpy change (ΔH), after which free energy 
change (ΔG) and entropy change (ΔS) can be calculated.44 While lower throughput, both 
of these techniques benefit from the fact that neither requires labeling of any sort.  
 
Biochemical techniques. HTS methods are desirable in order to increase 
efficiency in the search for hits against a rational target. Biochemical assays are naturally 
more amenable to supporting higher throughput screening than their biophysical 
counterparts. In contrast to biophysical assays, biochemical assays allow not only for the 
measurement of the affinity of test compounds for purified target protein, but also for the 
measurement of some biologically meaningful effect related to the overall function of the 
target enzyme.45 Moreover, biochemical assays can often be read in small volumes 
compliant high throughput plates and plate readers that make large numbers of repetitive 
assays possible, thereby introducing the possibility of screening entire libraries in very 
little amounts of time and covering as much chemical space as possible in the search for 
active compounds. Often, assays exist or can be developed that rely upon the 
measurement of some easily recorded change in absorbance, fluorescence, or 
luminescence via the exploitation of reactions involving components such as metabolic 
cofactors, fluorophores, and quenchers. Such assays not only allow for high throughput 





Target and hit validation and characterization techniques 
 
Once hit compounds are determined, a more thorough analysis of the target 
enzyme and the hit compound, as well as the interactive relationship between the two, 
can commence. A number of techniques exist to this end, and while it may be nearly 
impossible for a single lab or researcher to have a mastery of all of the following 
techniques, as well as access to the necessary respective instrumentations, the more 
techniques that can be employed, the more thorough understanding and knowledge 
pertaining to the target will be afforded. At minimum, however, a well-balanced and 
complementary combination of the following techniques are necessary. 
 
 Structural biology techniques. Various structural biology techniques exist that 
may be used for further biophysical characterization of a target protein and any 
significant interactions the target protein may make with various ligands. As would be 
expected, each technique carries with it its own benefits and liabilities, including 
administrative attributes like ease of use, access, and cost, as well as actual benefits and 
liabilities associated with the actual nature of the techniques and the application and 
results that can be expected from each. 
 
 X-ray crystallography. Considered the most powerful structure-guided drug 
discovery tool, X-ray crystallography offers a multitude of knowledge about the target 
protein down to the atomic level, with some crystal structures even determined and 
deposited in the protein data bank (PDB) with resolution below 1 Å.46 While structures at 
this high of a resolution are not overwhelmingly common, numerous structures exist in 
the PDB near the 2 Å resolution level, which allows not only overall structural features to 
be observed, but also finer features like peptide side chains and atomic interactions 
critical for structure-guided drug discovery. Cons to X-ray crystallography include the 
need to crystallize the target protein which, depending on the protein, may take 
substantial amounts of time (or simply never occur), may not yield high-quality 
diffracting crystals, and may not necessarily represent a biologically relevant 
conformation of the target protein; the need for access to a high-power X-ray source; as 
well as the substantial learning curve involved in procuring pure, homogenous protein, 
attaining high resolution diffracting crystals, data collection, data processing, and 
refinement. Nonetheless, the benefits of X-ray crystallography continue to outweigh the 
costs as it remains the indisputable golden standard for protein structure analysis. 
 
 Cryo-electron microscopy. Quickly becoming one of the most popular and 
powerful structural biology techniques available, cryo-electron microscopy (cryo-EM) 
has recently undergone substantial hardware, software, and methodology improvements 
that allow for near-atomic resolution biomacromolecular structure determination. 
Benefits of cryo-EM include the fact that the target protein does not need to be 
crystalized, which saves a substantial amount of time for the researcher and also allows 
structural analysis of the protein in an arguably more “biologically relevant,” or “near 
native” state.47 Limitations nonetheless include the requirement for pure, stable, and 
homogeneous protein; access to expensive equipment; substantial expertise; lower 
resolution structure determination relative to X-ray crystallography; and a high target 
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protein molecular weight cutoff limit relative to other major structural biology 
techniques.48 Though these last two issues represent major historical barriers to cryo-EM, 
which have traditionally included difficulty crossing the 2 Å resolution barrier and 
difficulty determining the structure of target proteins smaller than ~200 kilodaltons 
(kDa), recent reports exist of instances where the technique indeed produced results that 
broke each of these proposed barriers.49 As such, this technique is understandably gaining 
momentum, offering some utility in rational drug discovery efforts, with the potential for 
even greater utility to come. 
 
 Nuclear magnetic resonance spectrometry. Perhaps the final main structural 
biology technique worth discussing, nuclear magnetic resonance (NMR) spectrometry 
adds a significant amount of knowledge that complements the aforementioned techniques 
very well. While limitations indeed exist, such as a requirement for soluble protein, 
access to equipment and expertise, and a less practical general maximum target protein 
size cutoff limit of roughly 25 kDa, NMR is an extremely powerful modern tool used in 
drug discovery efforts. Unlike the other techniques mentioned, NMR offers the ability to 
characterize highly dynamic and disordered target proteins, the ability to analyze target 
enzyme activity in real-time, and the ability to effectively map specific binding site 
characteristics, among others.50-52 
 
 Enzymology techniques.  Thorough target protein characterization and validation 
requires a variety of different enzymology techniques. Functional biochemical assays are 
an absolute requirement for proper analyses of compound potency and the evaluation of 
mode of inhibition. A return to biophysical assays like thermal shift, ITC, and SPR is 
necessary for a proper assessment of binding kinetics.  
 
Iterative lead development techniques 
 
As the realistic terminal goal of any rational drug discovery campaign is the 
eventual development of lead compounds that can be carried on to clinical development, 
a fair amount of iterative rational compound optimization must occur. As a culmination 
of all pre-clinical development up to this point, it is understandable that SAR-guided 
chemical optimization should include all techniques heretofore discussed, as well as a 
few additional techniques.  
 
SAR-guided chemical optimization. Thorough analysis of structural data, ideally 
with a bound ligand, affords the researcher the opportunity to visualize the target enzyme 
and its corresponding active or allosteric site along with a previously discovered or 
developed ligand. This will allow for rational modification to the compound that allows 
the researcher to manipulate the compound to maximize characteristics like potency via 
improved or added non-covalent molecular interactions, solubility via rational addition of 
solubilizing groups at key positions, and so on. This allows for medicinal chemistry trials 
to commence, where newly synthesized rationally modified compounds can be tested via 




Virtual screening. Additional methods can also take place once structural data is 
obtained, including virtual screening, where significantly large computational libraries 
can be prepared and screened against the target protein via techniques like docking, 
pharmacophore matching, and shape matching. Any possibly improved and optimized 
compounds that result can then be synthesized or purchased and, again, tested against the 
target protein for potency assessment.  
 
Any gains or losses that result after classic “manual” SAR-guided optimization or 
virtual screening regarding potency and physicochemical attributes can be rationally 
weighed and evaluated. Then, the products can be rationally analyzed and further 
modified in an iterative fashion until a satisfactory product results that has, ideally, 
balanced an increased potency with satisfactory physicochemical properties that will not 
hamper the compound with respect to toxicology, metabolism, pharmacokinetics, or 
pharmacodynamics during future clinical trials and development.  
 
While it is unlikely that a researcher or research team would have access to 
expertise and equipment needed for every technique discussed above, a working 
combination is required and must be tailored to the specific rational target. Pros and cons 
of each technique must be considered, and a respectively appropriate research plan 
should commence based around which techniques are needed for project success and 
which techniques are available. While some techniques are absolute necessities, such as 
bioinformatics and protein production and purification, some but not all representatives 
from the other overarching technique categories can be mixed and matched. For example, 
depending on the specific research needs, while access to SPR may not exist, ITC may 
take its place; while cryo-EM may not be suited for a smaller protein target, X-ray 
crystallography may work well; and while biochemical assays utilizing absorbance may 
not be feasible, development of chemical probes or substrates that utilize specific 
fluorophores may be a possibility. As with most endeavors, the more knowledge and 
expertise one possesses, the more adaptability is afforded, and the more anticipated 
success exists. Consequently, it is arguable that access to enough knowledge, skills, and 
instrumentation would allow for any novel target to be engaged.  
 
 
Novel Narrow Spectrum Antibacterial Targets 
 
Whether the novel antibacterial target of interest is intended to be a broad 
spectrum target, a narrow spectrum target, or simply “anything we can get,” knowledge 
about the target itself is of paramount importance. In fact, before the actual pursuit 
begins, it is understood that a substantial amount of resources—time, energy, money—is 
going to be invested into the target. That is why, as mentioned above, a certain degree of 
anticipated success must accompany any real antibacterial drug discovery and 
development campaign. But, how can a researcher anticipate success when so little is 
known about a previously un-elucidated target? The only way, in fact, is to harvest as 
much knowledge about the target of interest in advance. This is, of course, important 
during rational drug discovery and development, but absolutely crucial when pursuing 




Pertinent questions include, but are not limited to, is the antibacterial target 
essential, or does its function at least dictate a significant degree of fitness to its host 
organism that could be exploited in some clinically significant manner? Perhaps it is an 
explicitly essential enzyme target. Or, perhaps it is instead a more cryptic target that 
confers some degree of fitness that can be taken advantage of and leveraged in high-stress 
biological situations, such as during immune response, concomitant antibacterial agent 
administration, or human microbiome supplementation and overcrowding. With respect 
to potential narrow spectrum targets, another pertinent question involves the existence—
or rather the absence—of the target in other bacteria that represent the beneficial 
members of the human microbiome. For the sake of selectivity, multiple beneficial 
scenarios could exist. First, it would be ideal if the target existed only in the genomes of 
only a few pathogens, thereby sparing beneficial bacteria from collateral damage and 
eradication. Alternatively, the gene responsible for the target enzyme could exist in 
bacteria other than the target pathogen, but perhaps the non-targeted bacteria possess 
bypass mechanisms that render that particular target non-essential in the respective 
bacteria under physiological conditions.  
 
Other pertinent preliminary questions of course involve the overall nature of the 
pathogen being targeted, such as site of infection, gram-stain classification, absence or 
presence of efflux pumps, and extent of pathogenicity. These types of questions may help 
guide anticipated physicochemical characteristics necessary for any future chemical 
probes or inhibitors, amongst others. Altogether, it is evident that the more preliminary 
knowledge a researcher has before commencing a rational antibacterial drug discovery 
campaign, the better. Once a requisite amount of preliminary knowledge is gained, a 
number of actual laboratory-based techniques are required for the successful discovery 
and development of rational antibacterial agents. 
 
Again, as our understanding of the human microbiome evolves, the deficiencies in 
traditional, broad-spectrum antibacterial therapy are becoming increasingly apparent. 
Both the advent of multi-drug resistant bacterial infections and the devastating 
disturbance of our normal bacterial ecology testify of the alarming need for novel 
antibacterial agents capable of selectively targeting pathogens, drug-resistant or 
otherwise, while mitigating the impact on beneficial and commensal organisms. As such, 
the benefit of narrow spectrum targets, which may afford opportunities for the killing or 
inhibiting specific pathogens without significantly inhibiting the growth of collateral or 
beneficial bacteria, is substantial. Engaging enzyme targets that meet these requirements, 
however, hinges upon exploiting intrinsic differences between the enzymatic proteomes 
of pathogenic bacteria and commensal bacteria—differences can be notably difficult to 
discern, thereby making the identification of such narrow spectrum antibacterial targets 
appropriately difficult.53,54 Two such potential targets follow.  
 
Bacterial topoisomerase I  
 
Bacterial topoisomerase I represents a potentially promising narrow-spectrum 
target as studies have arisen demonstrating its essentiality in bacterial species lacking the 
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only other type IA topoisomerase (topoisomerase III). With evidence supporting the 
bacterial essentiality of at least one type IA topoisomerase (topoisomerase I or 
topoisomerase III), an overlapping role between the two enzymes, and the fact that a 
select few pathogenic bacterial species solely possess topoisomerase I without 
topoisomerase III, the catalytic inhibition of bacterial topoisomerase I represents an 
attractive prospect for novel, selective antibacterial development.55-59 The streptococci 
are one of the few bacterial species that may possess topoisomerase I as their sole type IA 
topoisomerase and a representative, Streptococcus mutans, exists as a particularly 
promising candidate for the exploration and validation of topoisomerase I as a novel, 
selective antibacterial target.60-66 
 
Bacterial enoyl-acyl carrier protein (ACP) reductase II, FabK 
 
Bacterial enoyl-acyl carrier protein (ACP) reductase II, or FabK, is an enzyme 
within the bacterial fatty acid biosynthesis (FAS II) pathway that represents another 
highly promising narrow-spectrum target. Recent studies have demonstrated the 
essentiality of fabk gene that codes for enoyl-ACP reductase II (FabK) in C. difficile.67 
FabK is one of several disparate enoyl-ACP reductase isozymes (FabI, FabK, FabL, and 
FabV) that exists across bacteria.68-70 Additionally, recent data has shown that different 
regulatory systems control whether or not a bacterium is capable of bypassing FAS II 
inhibition via the uptake of exogenous fatty acids.71,72 Because FabK is the sole, essential 
enoyl-ACP reductase expressed in C. difficile, combined with the fact that different 
bacteria may possess an assortment of other enoyl-ACP reductase isozymes and 
regulatory systems, FabK from C. difficile represents a potential antibacterial target with 
particularly significant narrow-spectrum promise.  
 
Presented here are data investigating both the bacterial topoisomerase I and FabK 
enzymes as novel and potentially narrow spectrum antibacterial targets via validation and 
characterization studies using an array of drug discovery techniques, including structural 















Biological role of topoisomerases 
 
Topoisomerases are ubiquitous enzymes that help manage the diverse topological 
complications DNA undergoes during various biological processes. In general, the 
overall mechanism by which all topoisomerases function is centered around the initiation 
of controlled breaks in the DNA via temporary phosphodiester bonds between the 
substrate and a conserved catalytic tyrosine residue on the enzyme.73-75 The topological 
complications managed include negative and positive supercoils, catenated DNA rings, 
and various entanglements.75 There are a number of different topoisomerases that exist 
across all forms of life, which are organized into particular types and subtypes and serve 
varying biological roles. These roles may or may not overlap to a certain degree as they 
are carried out to address the different aforementioned topological complications in 
particular ways (Table 2-1).55,75-78 Type I topoisomerases exist as monomers that cause 
single DNA strand breaks and elicit topological change one link at a time via either a 
rotational or strand passage mechanism, and type II topoisomerases are multimers that 
require adenosine triphosphate (ATP) hydrolysis as an energy source in order to initiate 
double stranded breaks and facilitate DNA strand passage; whereas subtype A 
topoisomerases result in a 5’ phosphotyrosine DNA cleavage intermediate, and subtype B 
topoisomerases result in 3’ phosphotyrosine intermediates.55,75,79 Accordingly, 
topoisomerases are indispensable in their biological duties and, therefore, represent 
highly attractive and efficacious chemotherapeutic targets. While many human 
topoisomerases exist as well-validated and exploited anti-cancer targets, only a select few 
bacterial topoisomerases are currently exploited as useful antibacterial targets. 
 
Different bacterial topoisomerase targets   
 
Up to four topoisomerases can be present in the prokaryotic genome, two from the 
type IIA family and two from the type IA family. Type IIA topoisomerases are 
heterotetramers encoded by multiple genes (gyrA/B and parC/E), and type IA 
topoisomerases are monomers encoded by single genes—topA for topoisomerase I
                                                 
 
2 Adapted from final submission with permission from Elsevier Inc. Jones, J. A., Price, E., Miller, D. & 
Hevener, K. E. A simplified protocol for high-yield expression and purification of bacterial topoisomerase 
I. Protein Expr Purif 124, 32-40, https://doi.org/10.1016/j.pep.2016.04.010 (2016).73 
Adapted from final submission with open access permission from Elsevier Inc. Jones, J. A. & Hevener, K. 
E. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA topoisomerase I from the gram-
positive model organism Streptococcus mutans. Biochem Biophys Res Commun, 
https://doi.org/10.1016/j.bbrc.2019.06.034 (2019. In Press).74 
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Table 2-1. Overview of types and subtypes of select topoisomerases. 
 
 
DS, double stranded; SCs, supercoils; SS, single stranded 
Data sources: Champoux, J. J. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70, 369-413, 
https://doi.org/10.1146/annurev.biochem.70.1.369 (2001).75 
Pommier, Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol 8, 82-95, https://doi.org/10.1021/cb300648v (2013). 
Slesarev, A. I. et al. DNA topoisomerase V is a relative of eukaryotic topoisomerase I from a hyperthermophilic prokaryote. Nature 
364, 735-737, https://doi.org/10.1038/364735a0 (1993).55  
Wendorff, T. J. & Berger, J. M. Topoisomerase VI senses and exploits both DNA crossings and bends to facilitate strand passage. 
Elife 7, https://doi.org/10.7554/eLife.31724 (2018).77 
 




Topo I  Bacteria Relax - SCs 
5’ 
Torsional strain Monomer 
Topo III Bacteria Decatenation, relax - SCs Torsional strain Monomer 
Topoisomerase IIIα  Mammalian Relax - SCs Torsional strain Monomer 
Topoisomerase IIIß  Mammalian Uncertain Torsional strain Monomer 
Reverse gyrase Archaea, other Cause + SCs ATP Heterodimer 
B Topoisomerase I Mammalian Various, relax +/- SCs 
3’ 
Torsional strain Monomer 




Topo II/Gyrase Bacteria Introduce - SCs 
5’ ATP 
Heterotetramer 
Topoisomerase IV Bacteria Relax - SCs, decatenation Heterotetramer 
Topoisomerase IIα Mammalian Decatenation Homodimer 
Topoisomerase IIß Mammalian Various Homodimer 
B Topoisomerase VI Archaea Relax +/- SCs, decatenation Heterotetramer 
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topB for topoisomerase III.55,80 Only two bacterial topoisomerases—the type IIA 
topoisomerases known as gyrase and topo IV—have inhibitors that have been developed 
and marketed as antibacterial drugs.55 These type IIA topoisomerases stand as very well-
established and well-validated antibacterial targets via the quinolone class of 
topoisomerase poisons, which form bactericidal topoisomerase-DNA-quinolone ternary 
complexes and result in broad-spectrum antibacterial activity. In contrast, the type IA 
topoisomerases—topoisomerase I and topoisomerase III—remain relatively unexplored 
from a drug discovery and development standpoint and are consequently without 
respectively approved inhibitors.55 Current efforts are being undertaken, however, to 
discover and develop novel bacterial topoisomerase IA inhibitors.81  
 
As evolutionary paralogues, topoisomerase I and topoisomerase III are believed to 
have arisen via gene duplication and, therefore, reasonably exemplify a certain degree of 
functional overlap.82 Topoisomerase I exists in all bacteria to relax negative DNA 
supercoils, while topoisomerase III is only found in some bacteria and is primarily geared 
toward decatenation (Table 2-2).78 Nevertheless, it has been shown that E. coli strains 
possessing the genes for both topoisomerase I and topoisomerase III (topA and topB, 
respectively), while comparatively less fit, are able to survive topA gene deletion 
mutations, but strains lacking the topB gene showed no such viability.83 The scientific 
deduction made herein is that when topoisomerase I activity is negated in some way, the 
residual topoisomerase III enzyme, if present, is capable of relieving the resultant insult, 
thereby maintaining viability and fitness to some extent and acting as a sort of enzymatic 
levee. This concept introduces the hypothesis that, on top of the potential broad-spectrum 
fitness cost of topoisomerase I inhibition across all species of bacteria, specific 
topoisomerase I inhibitors could have the added effect of showing selectivity against 
organisms that possess the topA gene in absence of the topB gene (Figure 2-1).  
 
 
Type IA Topoisomerases in Streptococci 
 
Several clinically relevant bacteria exist that possess topA without topB and, 
therefore, express topoisomerase I as their sole type IA topoisomerase. Examples include 
Acinetobacter baumanii, Francisella tularensis, Helicobacter pylori, Legionella 
pneumophila, Mycoplasma pneumoniae, and Mycobacterium tuberculosis.78 The 
clinically relevant streptococci were also long thought to possess topA without topB. 
However, recent provisional streptococcal topoisomerase III protein sequence depositions 
in the National Center for Biotechnology Information (NCBI) database have surfaced that 
now suggest otherwise. Further bioinformatic analysis, though, suggests at least the 
possibility that the streptococcal topo III protein sequences found in NCBI may be 
misannotated as there is no NCBI-annotated streoptococcal topB gene.84 Furthermore, a 
Basic Local Alignment Search Tool (BLAST) nucleotide-to-nucleotide “blastn” analysis 
of the E. coli topB gene (accession no. CP009685.1) against the genome of the Gram-
positive model organism Streptococcus mutans (taxid: 1309), returned no significant 
similarities.84,85 Similarly, a BLAST protein-to-nucleotide “tblastn” analysis of the 












S. mutans X ? X X 
A. baumannii X - X X 
F. tularensis X - X X 
H. pylori X - X - 
L. pneumophila X - X X 
M. pneumoniae X - X X 
M. tuberculosis X - X - 
B. anthracis X X X X 
C. difficile X X X - 
E. coli X X X X 
E. faecalis X X X X 
H. influenzae X X X X 
K. pneumoniae X X X X 
N. gonorrhoeae X X X X 
P. aeruginosa X X X X 
S. aureus X X X X 
Y. pestis X X X X 
 
Data source: Forterre, P., Gribaldo, S., Gadelle, D. & Serre, M. C. Origin and evolution 











Figure 2-1. S. mutans topoisomerase I structural homology model.  
 
Full structure of the SmTopoI enzyme (blue ribbons) with the N-term (green) and flexible 





NCBI against the S. mutans UA159 genome (taxid: 210007) only showed a 27.6% 
identity match with the S. mutans complete genome (accession no. AE014133.2), which 
may possibly represent a low-grade match to the nucleotide sequence for another DNA-
binding enzyme from S. mutans such as, but not necessarily, topA.84,85 An open protein-
to-protein “blastp” search of the NCBI annotated S. mutans topo III protein (accession 
no. SUN72613.1), however, returned a substantial number of topo III protein sequence 
matches from other streptococci that range from 65.46 to 98.45%.85 While an uncertainty 
indeed lingers around the presence or absence of topB in S. mutans, substantial utility still 
remains in studying the topo I enzyme from this useful organism. 
 
If S. mutans does in fact possess topo I as its sole type IA topoisomerase, then it 
would serve as a particularly promising subject for the validation of topo I as an effective 
narrow-spectrum antibacterial drug target. In contrast, if it turns out S. mutans actually 
expresses topo III as well, topo I from S. mutans (SmTopoI) may, for the time being, still 
act as a useful surrogate antibacterial target for amassing information regarding the 
druggability of topo I that may later be translated to other bacteria that are confirmed to 
express topo I as their sole type IA topoisomerase. Therefore, either way, the 
investigation of SmTopoI serves as a promising head start for the characterization and 
validation of topoisomerase I as a selective antibacterial target. This research thereby 
endeavors to use S. mutans to address remaining gaps in knowledge relating to key 
structural evidence substantiating the druggability of topoisomerase I in general.  
 
As a representative of the viridans group streptococci (VGS) and a Gram-positive 
model organism, S. mutans exists as an excellent candidate for the initial exploration and 
validation of topo I as a novel antibacterial target.60-66 VGS are represented by a plurality 
of heterogeneous streptococcal organisms that constitute a common component of the 
human microbiome found primarily within the oral cavity and upper respiratory tract, as 
well as in the gastrointestinal tract and female genitourinary tract.86,87 With historically 
low consideration for pathogenicity, VGS have been increasingly implicated in a wide 
array of problematic diseases such as endocarditis, pneumonia, cellulitis, bacteremia, and 
viridans streptococcal shock syndrome, among others.86,88 Moreover, VGS stand as the 
predominant group of microorganisms within the oropharynx, with a member of the 
group, S. mutans, representing the main culprit in dental cariogenesis.89 Considering the 
vast clinical and economic burdens now known to be caused by VGS, the necessity for 
effective antibacterials targeting these pathogens has escalated. While the majority of 
VGS infections are still susceptible to penicillin, the proliferation of drug-resistant VGS 
organisms, including those resistant to penicillins, macrolides, and lincosamide 
antibiotics, is becoming more of a concern.86,87 Additionally, as the beneficial bacteria 
that cohabitate the usual sites of VGS residence are concomitantly eradicated by the 
traditional use of these broad-spectrum antibacterials, significant collateral consequences 
such as candidiasis and Clostridioides difficile infections have increased over time.90-92  








As most bacterial topo I inhibitors published to date are general DNA-binding 
agents, they would be expected to show poor selectivity for individual type IA 
topoisomerases.56 With that in mind, there are two known direct mechanisms for 
topoisomerase inhibition. First is the formation of aforementioned cytotoxic 
“topoisomerase poisons” that form ternary enzyme-DNA-inhibitor complexes and 
prevent the rejoining of transiently cleaved DNA strands. The second mechanism is 
catalytic inhibition via competition at the allosteric ATP site, or direct competition at the 
active DNA site. As type IA topoisomerases act independently of ATP, any catalytic 
inhibition would likely need to be accomplished by specifically targeting the DNA active 
site. While the majority of published direct bacterial topoisomerase I inhibitors have been 
shown to be “topoisomerase poisons,” scientific precedent does exist for catalytic 
bacterial topoisomerase I inhibition via direct DNA competition.93,94 As such, this 
research focuses on characterizing the DNA active site of SmTopoI as the first step in 
rationally providing evidence of the possibility of selective topoisomerase I druggability. 
Accordingly, a thorough structural understanding of the target enzyme is required to 
identify key determinants of substrate and inhibitor binding along the DNA active site. 
Such knowledge would support future efforts for the identification of novel chemical 
probes and support the druggability of bacterial topoisomerase I. To gain such an 
understanding, the structural determination of the enzyme at atomic resolution is 
necessary. Substantial initial hurdles exist, however, as topo I is a DNA binding enzyme 
and, as such, has been proven throughout the literature to be a highly difficult target 
enzyme to purify and crystallize.95-97  
 
Unfortunately, additional difficulties also exist that are unique to targeting topo I. 
For example, unlike the ATP-dependent type IIA topoisomerases, the ATP-independent 
type IA topoisomerases catalyze an energetically favorable event and rely solely on the 
torsional strain of their DNA substrate to generate the energy required to carry out their 
biological responsibilities relaxing hyper-negative supercoils or decatenating interlinked 
DNA.55 This fact carries with it multiple liabilities. First, unlike the type IIA 
topoisomerases, there is no opportunity to measure the expenditure of an energy source 
when targeting type IA topoisomerases. As such, the only way to measure the activity of 
the topo I enzyme, and in turn measure the inhibition of its activity, is by measuring the 






Protein Expression and Purification of SmTopoI 
 
As mentioned above, inherent difficulties are involved with the purification of 
DNA-binding proteins such as bacterial topoisomerase I. The initial need to separate 
cellular DNA from the target enzyme introduces an early obstacle in the protocol. To 
overcome such an obstacle, previous methods including treating extracts to batch anion 
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exchange, DNase treatments, and DNA precipitations using different compounds like 
streptomycin sulfate and polyethyleneimine have been employed.98 While each DNA-
separation method has its own advantages and disadvantages, they all share a certain 
degree of costliness with respect to time and resources. Previous studies regarding the 
expression and purification of bacterial topoisomerase I have yielded varied results. 
While truncated N-terminal fragments of E. coli topoisomerase I have been well studied 
and characterized, the full-length enzyme is desirable for thorough characterization and 
inhibitor development.99,100  In one study, the purification and analysis of full-length 
topoisomerase I from the extremophile Thermotoga maritima was carried out (expressed 
in E. coli with IPTG induction; heated to precipitate non-thermophile proteins and DNA; 
purified using a heparin column followed by size exclusion chromatography) and yielded 
2-3 mg/Liter.101,102  However, information gleaned from an extremophile would not 
necessarily be expected to provide data that could be reliably applied to clinically 
relevant bacteria. Another study detailed the purification of full-length topoisomerase I 
from Streptococcus pneumonia (expressed in E. coli with IPTG induction followed by 
dialysis, IMAC purification, and a second dialysis step), but did not report yield.93  
Despite their noteworthy contributions to our understanding of bacterial topoisomerase I, 
these studies either failed to report the amount of protein yielded from their respective 
protocols, or the yield was relatively low, making biophysical and biochemical assay 
studies logistically difficult. A study developing the purification of topoisomerase I from 
E. coli yielded a significant amount of the enzyme, but would not be appropriate for 
expressing and purifying topoisomerase I from non-E.coli bacteria as the protocol lacked 
a method for separating non-native enzyme from native.103 More recent studies discussed 
the purification of full-length E. coli and Mycobacterium tuberculosis topoisomerase I 
used for the subsequent crystallization and characterization of the respective enzymes, 
but did not report the yields.95,96 
 
Herein, the expression, rapid two-step purification, and preliminary 
characterization of full-length topo I from S. mutans with yields significantly greater than 
previously reported purifications of bacterial topoisomerase I are reported. Notably, the 
expression protocol requires significantly less effort than classical induction methods and 
the purification protocol bypasses traditionally cumbersome DNA-removal methods and 
can be carried out in a single day with an estimated purity of 95% or higher.  
 
 
Structural Determination of SmTopoI_N65 
 
As overall interest in type IA topoisomerases continues to increase, especially 
with regard to efforts aimed at discovering and developing novel antibacterial agents—
particularly topo I inhibitors—the need for a greater amount of structural topo I data 
becomes more apparent.56,57,93,97,104 Aiding in these efforts, several three-dimensional 
apo- and co-crystal structures of topo I from various bacterial species have been 
determined, including those from the gram-negative model organism E. coli (EcTopoI),96 
the gram-negative extremophile Thermotoga maritima (TmTopoI),101 and the uniquely 
non-gram-classified Mycobacterium tuberculosis (MtTopoI).95  
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Though E. coli prevails as the predominant model organism in microbiological 
research, inherent differences exist between gram-negative and gram-positive bacteria. 
Accordingly, as Streptococcus mutans has gained utility as a gram-positive model 
organism,105 efforts were undertaken to obtain diffraction-quality full-length S. mutans 
topo I (SmTopoI) protein crystals. Though, similar to other topo I crystallization 
campaigns reported in the literature, such efforts were met with initial difficulty.95,96 
Therefore, rational constructs of main body N-terminal fragment of SmTopoI were 
cloned and expressed to remove the flexible C-terminal domain and improve chances of 
crystallization. This eventually led to a 65-kDa fragment (SmTopoI_N65) that yielded 
high diffraction-quality crystals used for structural characterization of SmTopoI. Herein 
the three-dimensional crystal structure of SmTopoI_N65, the first topo I structure 
determined from a gram-positive bacterium and its corresponding structural 
characterization are reported. 
 
 
Materials and Methods 
 
 
Reagents, Chemicals, Biologicals, and Equipment 
 
Biological materials, equipment, and reagent-grade chemicals used were from the 
following sources: Streptococcus mutans genomic DNA, ATCC® 700610D-5™ from 
ATCC® (Manassas, VA); ArcticExpress(DE3) Competent Cells, pUC18 plasmid, XL1-
Blue Supercompetent cells, and BL21(DE3)-Gold Competent cells from Agilent 
Technologies (Santa Clara, CA); ChampionTM pET SUMO Protein Expression System, 
including One Shot® Mach1TM-T1R and BL21(DE3) One Shot® Chemically Competent 
E. coli cells from invitrogenTM by Life TechnologiesTM (Carlsbad, CA); HyperLadder™ 
1kb Plus from Bioline USA Inc (Taunton, MA); pET-15b vector, pET-16b vector, and 
pET-21d vector from Novagen® EMD Millipore® (Billerica, MA); Quick LigationTM 
Kit, BamHI, NdeI, and NcoI restriction enzymes from New England Biolabs, Inc. 
(Ipswich, MA); DifcoTM LB, Miller and Terrific Broth from BDTM (Franklin Lakes, NJ); 
Thermo Scientific™ GelCode™ Blue Safe Protein Stain and SpectraTM Multicolor High 
Range Protein Ladder from Thermo Fisher Scientific (Waltham, MA); HiMark™ Pre-
stained Protein Standard, Novex™ InVision™ His-Tag In-Gel Stain, Platinum® PCR 
SuperMix High Fidelity, NuPAGE® Novex® 3-8% Tris-Acetate Protein Gels, Novex™ 
NuPAGE™ LDS Sample Buffer (4X), and Novex™ NuPAGE™ Tris-Acetate SDS 
Running Buffer and Molecular ProbesTM SYPROTM Orange Protein Gel Stain from 
InvitrogenTM by Life TechnologiesTM (Carlsbad, CA); QIAGEN Plasmid Maxi Kit, 
QIAquick PCR Purification Kit, and QIAprep Spin Miniprep Kit from Qiagen (Valencia, 
CA); DTT, glycerol, IPTG, lysozyme, NaCl, MgCl2, protease inhibitor tablets (EDTA-
free), Tris, Tris base, and Triton X-100 from Fisher Scientific (Pittsburgh, PA);DNase I 
from Worthington Biochemical Corporation (Lakewood, NJ); ampicillin, kanamycin, and 
KH2PO4 from Acros Organics, part of Thermo Fisher Scientific (Waltham, MA); 30,000 
MWCO Amicon™ Ultra-15 Centrifugal Filter Units and Imidazole from EMD 
Millipore® (Billerica, MA); K2HPO4 from Sigma Aldrich (St. Louis, MO); GelRed™ 
nucleic acid gel stain from Biotium, Inc. (Hayward, CA); primers synthesized by 
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Integrated DNA Technologies (Coralville, IA); Hampton Solubility & Stability Screen 
2TM from Hampton Research (Aliso Viejo, CA). ÄKTA Purifier FPLC, HisTrap-HP 5 
mL column, and HiLoad 26/600 Superdex 200 PG size exclusion column from GE 





The mini-expression lysis buffer is composed of 75 uL of 1% n-octyl beta-D-
thioglucopyranoside (OTG) in 20 mM Tris HCl (pH 7.5), 0.1 mg Lysozyme, 0.1 mg 
DNase I, and 0.5 uL of 0.5 M MgCl2 for one cell pellet.  The 2x LDS dye is composed of 
5 mL Novex™ NuPAGE™ LDS Sample Buffer (4X), 500 mM DTT, and brought to 10 
mL with ddH2O.  The standard lysis buffer is composed of 20 mM sodium phosphate (pH 
7.4), one Pierce® EDTA-free protease inhibitor tablet per 50 mL, 1 mM DTT, 0.5% 
Triton X, 0.5 M NaCl, 5% glycerol, 0.5 mg/mL lysozyme, 5µg/mL DNase, and 5 mM 
imidazole.  Lysis buffer 2 is composed of standard lysis buffer without DNase I.  Buffer 
A is composed of 20 mM sodium phosphate (pH 7.4), 0.5 M NaCl, 5 mM imidazole, and 
5% glycerol.  Buffer B is composed of 20 mM sodium phosphate (pH 7.4), 0.15 M NaCl, 
250 mM imidazole, and 5% glycerol.  The size exclusion buffer is composed of 50 mM 
sodium phosphate (pH 7.4) and 150 mM NaCl.  Buffer C is composed of buffer A with 
1M NaCl.  Buffer D is composed of buffer B with 0.5M NaCl and 350 mM imidazole.  
Size exclusion buffer 2 is composed of 20mM Tris (pH 8.0), 1 mM MgCl2, 0.5M NaCl, 
and 1 mM DTT.  The gel assay buffer and assay stop buffer were prepared as previously 
reported.104  The gel assay buffer is composed of 10mM Tris pH 8.0, 50mM NaCl, and 6 
mM MgCl2.  The assay stop buffer is composed of 50mM EDTA, 50% glycerol, and 
0.5% w/v bromophenol blue.   
 
 
SmTopoI Cloning and Plasmid Construction 
 
Initially, the topA gene was cloned from Streptococcus mutans UA159 genomic 
DNA for insertion into the pET-15b vector based for the NdeI and BamHI restriction 
sites using the following primers: 
 
TopA_Forward: 5’-TGT AGA CAT ATG ACA AGT AAA ACA ACG ACA ACA-3’ 
 
TopA_Reverse: 5’-TCA TCA GGA TCC TTA TTT AAC AGC TTT TTC CTT-3’ 
 
PCR was carried out via Platinum® PCR SuperMix High Fidelity protocol and denatured 
at 94 oC for 30 seconds, annealed at 58 oC for 40 seconds, and extended at 68 oC for two 
minutes for 30 cycles and then held at 4 oC. Success was analyzed via 1% agarose gel 
electrophoresis based upon the confirmed presence of the ~2Kbp SmTopA_pET PCR 
product. SmTopA_pET was then purified using QIAQuick® PCR Purification Kit per 
protocol. The pET-15b vector was then digested with NdeI and BamHI restriction 
enzymes per New England Biolabs (NEB) protocol, purified, then mixed and ligated with 
the SmTopA_pET PCR product via NEB Quick LigationTM Kit protocol. The ligation 
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product (SmTopA15b) was then transformed into XL1-Blue Supercompetent cells per 
protocol. Upon successful transformation, the plasmid was isolated with the QIAprep 
Spin Miniprep Kit via protocol and the sequence was confirmed via Retrogen, Inc. (San 
Diego, CA). The plasmid was also transformed into BL21(DE3)-Gold Competent cells 
via protocol.  
 
The topA gene was sub-cloned from the pET-15b vector in XL-1 Blue into the 
pET-16b vector using NdeI and BamHI restriction enzymes and NEB Quick LigationTM 
Kit per manufacturer protocols.  
 
For the pET 21d vector, the SmTopA gene was amplified via PCR around NcoI 
and BamHI restriction sites using the following primers: 
 
NcoI_Site_For: TAT ACG ATG GGC AGC AGC CAT CAT C 
 
NdeI_Site_For: GGC AGC CCC ATG GCA AGT AAA AC 
 
BamHI_Site_Rev: TTC GGA TCC TTT TTA ACA GCT TTT TCC TTA TAG TCA 
CAC 
 
PCR was carried out via Platinum® PCR SuperMix High Fidelity protocol and denatured 
at 94oC for 30 seconds, annealed at 58oC for 45 seconds, and extended at 68oC for two 
minutes and thirty seconds for 35 cycles and then held at 4 oC. 
 
 For the pET-SUMO vector, the topA gene was cloned from PCR with “hanging 
T” ends per ChampionTM pET SUMO Protein Expression System protocol using the 
following primers: 
 
TopA_SUMO_For: AGC ACA AGT AAA ACA ACG ACA ACA GTA AAA AAG 
ACG 
 
TopA_SUMO_Rev: TTA TTT AAC AGC TTT TTC CTT ATA GTC ACA CTC 
CTT ATT GC 
 
PCR was carried out via Platinum® PCR SuperMix High Fidelity protocol and denatured 
at 94oC for 30 seconds, annealed at 60oC for 45 seconds, and extended at 68oC for two 
minutes and thirty seconds for 35 cycles and then held at 4 oC. 
 
All gene and respective plasmids were ligated and transformed per respective 
protocols per respective protocols into XL1-Blue Supercompetent cells and BL21(DE3)-
Gold Competent cells except the SmTopA_SUMO plasmid used with the ChampionTM 
pET SUMO Protein Expression System, which utilized included One Shot® Mach1TM-
T1R and BL21(DE3) One Shot® Chemically Competent E. coli cells. Sequences were 





Mini-Expression of SmTopI15b 
 
A mini-expression was initially conducted in order to determine preliminary 
expression conditions, starting with a 5-mL LB and 100 ug/mL starter culture of 
SmTopI15b in BL21(DE3)-Gold grown at 32oC overnight. Upon the next day, the sample 
was diluted 100-fold into three 5-mL sterile TB and 100 ug/mL ampicillin samples for 
each of three different temperatures: 37oC, 25oC, and 18oC. Cultures were then grown for 
two hours, then one sample from each temperature was induced with 1 mM IPTG, one 
with 0.5 mM IPTG, and one remained un-induced. Samples were then grown an 
additional twenty-four hours, then centrifuged at 10,000 rpm for five minutes. The 
supernatant was then removed and each pellet was dissolved in Mini_Lysis_Buffer for 
five minutes. Cells were re-suspended and vortexed for 30 seconds to completely 
dissolve and the samples were centrifuged at 13,000 rpm for five minutes. The 
supernatants were then separated into clean 1.5 mL microcentrifuge tubes as the soluble 
fractions. Pellets were washed by re-suspending in 30 uL of 1% OTG in 20 mM Tris (pH 
7.5) and centrifuging at 13,000 rpm for five minutes. The supernatant was then discarded. 
Pellets were once again re-suspended in 30 uL of 1% OTG in 20 mM Tris (pH 7.5) and 
mixed with 30 uL of LDS_Sample_Buffer, then centrifuged again at 13,000 rpm for five 
minutes with the resulting supernatant containing the insoluble fraction. 10 uL samples 
were then heated at 95oC for five minutes and loaded on SDS-PAGE gels for analysis.  
Mini-expression was repeated for 48-hour growths as well. (Data not shown.) Mini-
expression was again repeated with SmTopI16b at 18oC.  
 
 
Expression of SmTopoI constructs and cell lysis 
 
Expression and purification experiments were conducted in duplicate. SmTopI15b 
initial starter cultures were grown in BL21 cell lines at 32°C overnight in 5-mL LB with 
100 ug/mL ampicillin (pET constructs) or 50 ug/mL kanamycin (SUMO construct) and 
used to inoculate 500mL TB with respective antibiotics. Cultures were grown to OD600 
~0.6, induced with 0.5 mM IPTG, and expressed at 18°C for 24 hours. Auto-induction 
was carried out per Studier protocol with SmTopI16b and grown for 24 hours at 37°C.106  
All samples were then centrifuged at 15,000 g for 30 minutes at 4oC and the supernatants 
were discarded. Pellets were stored at -80oC.  
 
Cell pellets for all constructs were thawed at room temperature and immediately 
lysed in the standard lysis buffer by stirring for 1 hour at 4°C.  Samples were then 
sonicated for 8 minutes, centrifuged at 18K rpm at 4°C for 15 minutes, filtered at 0.22 
um, and collected.  Auto-induction samples were lysed in the same fashion, except lysis 
buffer 2 was used, and then samples were sonicated and filtered as above.  
 
 
Purification of SmTopoI constructs  
 
Each initial construct sample was purified using a HisTrap-HP 5 mL column on 
an ÄKTA Purifier FPLC. Samples were loaded at 1 mL/min, washed with 20 column 
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volumes (CVs) Buffer A at 2.5 mL/min, and eluted via linear gradient from 100% Buffer 
A to 100% Buffer B over 20 CVs at 2.5 mL/min. Samples were then collected and 
concentrated using a 30,000 MWCO Amicon™ Ultra-15 Centrifugal Filter Unit. The 
SmTopI16b sample was collected and loaded onto a GE HiLoad 26/600 Superdex 200 
PG size exclusion column and eluted with 1.5 CV of SE Buffer. The sample expressed 
via auto-induction (SmTopI16b_AI) was purified similarly, except it was loaded and 
washed with Buffer C for 40 CVs and eluted with a step gradient of Buffer D using 7CV 
steps at 15%, 20%, and 100% with the sample eluting in a sharp peak in the 100% step. 
The sample was then loaded onto a pre-equilibrated GE HiLoad 26/600 Superdex 200 PG 
size exclusion column and eluted with SE Buffer 2. All sample concentrations were 





Gel assays were used to confirm target protein activity using published 
methods.104 The pUC18 plasmid was isolated via QIAGEN Plasmid Maxi Kit per 
protocol. Enzyme assays were conducted in standard volumes of 20µL comprised of 25, 
50, 75, 100, 150, 200, or 400 ng SmTopI; 500 ng negatively supercoiled pUC18 plasmid; 
and a sufficient quantity of gel assay buffer to bring the reaction volume to 20 uL. One 
unit of commercially obtained E. coli topoisomerase I was substituted for SmTopI as a 
positive control. Assays were incubated at 37⁰C for 30 minutes and then terminated using 
5µL of assay stop buffer per reaction. DNA relaxation activity was monitored on 0.7% 
agarose gels in Tris-Acetate-EDTA TAE buffer at 20V for 10 hours and then stained with 
GelRed™ nucleic acid gel stain per protocol. Freeze trials were conducted similarly using 
1 ug (high concentration) or 400 ng (low concentration) of enzyme in 50% glycerol or 
0% glycerol and either snap-frozen in liquid nitrogen, frozen drop-wise in liquid nitrogen 
and stored at -80oC overnight, or simply refrigerated. Non-specific DNAse activity assay 
was conducted using published methods and incubated for 6 hours.103  
 
 
Thermal Stability Assay 
 
Protein stability and solubility conditions were analyzed via the use of Hampton 





Target protein identity was confirmed by standard in-gel tryptic digest and LC-
MS analysis.107-109 Peptide spectra matching and protein identification was achieved by 






SmTopoI Protein Homology Modeling 
 
A homology model of the SmTopoI protein (Figure 2-1) was built using the E. 
coli 67-kDa N-term fragment (1ECL) and T. maritima (2GAI) topoisomerase I crystal 
structures as templates, the Streptococcus mutans (UA159 strain) protein sequence, and 
the program MODELLER.110,111 
 
 
SmTopoI_N65 Cloning, Expression, Purification and Crystallization 
 
SmTopoI_N65 was cloned, expressed, and purified to over 95% purity via PAGE 
analysis similarly to full-length SmTopoI described elsewhere.73,74 However, the target 
construct gene of interest, topA_N65, was amplified via PCR off of the topA-containing 
SmTopI_16b plasmid from above based around the NdeI and BamHI restriction sites 
using the following primers:  
TopA_Forward: 5′-TGT AGA CAT ATG ACA AGT AAA ACA ACG ACA ACA 
G-3′ 
TopA_N65_Rev: 5’-GGA TGG ATC CTT ACT GTT CCT CTG C-3’ 
The gene was ligated into a pET-15b vector (Novagen® EMD Millipore®, 
Billerica, MA) and the target plasmid was transformed into BL21(DE3)-Gold Competent 
cells (Agilent Technologies, Santa Clara, CA) per the manufacturer’s specified protocol. 
The target enzyme was expressed via auto induction and purified per previous protocol, 
except Tris was substituted for all phosphate buffers.73,106 Briefly, cells were lysed for 1 
hour at 4°C in Lysis Buffer composed of 20 mM Tris-hydrochloride (HCl) pH 8.0, one 
Pierce® EDTA-free protease inhibitor tablet per 50 mL, 1 mM DTT, 0.5% Triton X, 0.5 
M NaCl, 5% glycerol, 0.5 mg/mL lysozyme, and 5 mM imidazole, then sonicated, 
centrifuged, and filtered at 0.22 m. Hexa-his-tagged protein was purified using a 
HisTrap-HP 5 mL column on an ÄKTA Purifier FPLC (GE Healthcare Lifesciences, 
Pittsburgh, PA) via step-gradient nickel immobilized metal affinity chromatography 
(IMAC) in Buffer A, composed of 20 mM Tris-HCl pH 8.0, 1 M NaCl, 5 mM imidazole, 
and 5% glycerol, and Buffer B, composed of 20 mM Tris-HCl pH 8.0, 0.5 M NaCl, 350 
mM imidazole, and 5% glycerol. The sample was then purified on a GE HiLoad 26/600 
Superdex 200 PG size exclusion chromatography (SEC) column in SEC Buffer, 
composed of 20 mM Tris (pH 8.0), 1 mM MgCl2, 0.5 M NaCl, and 1 mM DTT. Target 
protein fractions were pooled, concentrated with a 10,000 MWCO  AmiconTM Ultra-15 
Centrifugal Filter Unit from EMD Millipore® (Billerica, MA) and used for 
crystallography.  
 
SmTopoI_N65 was crystallized at 4.6 mg mL-1 in a 3uL:3uL 1:1 ratio protein to 
condition using the hanging-drop vapor-diffusion method off of a coarse-matrix screen. 
The initial crystal growth condition was JCSG-plus (Molecular Dimensions, Maumee, 
OH) condition 1-5 (0.2 M magnesium formate dihydrate, 20% w/v PEG 3350) at 18°C. A 
1:1 mixture of Izit Crystal Dye (Hampton Research, Aliso Viejo, CA) and acid red dye 
was added to original crystal-containing drops and allowed to stain overnight for 
preliminary crystal assessment. Unstained crystals from the same well, but from a 
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different drop, were collected for X-ray diffraction analysis. Initial crystals showed 
relatively weak diffraction (greater than 4 Å). Optimized crystals were then obtained via 
fine grid screen in 0.2 M magnesium formate dihydrate, 25% w/v PEG 3350 at 4°C and 
unstained crystals were collected for analysis. Crystals were grown in 48-well VDX 




SmTopoI_N65 Structure Determination and Refinement 
 
SmTopoI_N65 crystals were harvested, looped through 20% w/v PEG 3350/30% 
MPD in the crystallization condition for cryo-protection, and cooled to 100 K for data 
collection. A complete data set was collected at GM/CA-CAT beamline 23ID-D of sector 
23 of the Advanced Photon Source (APS), Argonne National Laboratory, Lemont, 
Illinois, USA (Table 2-5). Data were processed and scaled, then the structure of 
SmTopoI_N65 was determined via molecular replacement using the previously 
determined 67-kDa N-terminal fragment of EcTopoI (PDB 1ECL)100 all using the HKL-
3000 suite.112 Initial automatic model building was performed within HKL-3000 using 
Buccaneer.112,113 Refinement was then conducted using phenix.refine and the model was 
further built out using AutoBuild from the PHENIX suite.114 Subsequent refinement and 
model building was conducted iteratively with phenix.refine and Coot.114,115 Late-stage 
automated re-refinement was conducted using PDB_REDO.116 Validation of the structure 
was conducted within PHENIX using MolProbity.117 Figure 2-14 was produced with the 
UCSF Chimera package.118 
 
 
TopoI Sequence and Structure Alignments  
 
SmTopoI_N65, EcTopoI_N67, EcTopoIII (PDB 1D6M), and MtTopoI sequence 
alignment was generated with the ESPript 3 server (http://espript.ibcp.fr/) using a 
multiple protein sequence alignment produced with Clustal Omega, with secondary 
structure information extracted from the SmTopoI_N65 structure.119,120 Residues within 
5Å of the active site Y316 were determined with UCSF Chimera and the structure 
distances measurement tool.118 Structural alignment of SmTopoI_N65 with 
EcTopoI_N67 (PDB 1ECL) and MtTopoI (PDB 5UJ1) conducted with UCSF Chimera 
MatchMaker structure comparison tool.100,101,118 
 
 
Generation of SmTopoI_N65 Topology Model 
 
The SmTopoI_N65 topology model was generated with PDBsum and SmTopoI_N65.pdb 





SmTopoI_N65 Multiple Sequence Alignment with Select Topo I Homologs of 
Undetermined Structure 
 
SmTopoI_N65, EcTopoI_N67, and MtTopoI sequence alignment was generated 
similarly as done described in the main manuscript with the ESPript 3 server 
(http://espript.ibcp.fr) using a multiple protein sequence alignment produced with Clustal 
Omega, with secondary structure information extracted from the SmTopoI_N65 
structure.119,120 Residues within 5Å of the active site Y316 were determined with UCSF 
Chimera and the structure distances measurement tool.118  
 
 
Structural Alignment of SmTopoI_N65 and TmTopoI (PDB 2GUI) 
 
Structural alignment of SmTopoI_N65 with TmTopoI (PDB 2GUI) conducted 
with UCSF Chimera MatchMaker structure comparison tool.101,118 The unique loop 
extension near the active site of SmTopoI_N65 is highlighted with a red circle. 
 
 
SmTopoI_N65 Sequence Alignment with EcTopoIII (PDB 1D6M) 
 
SmTopoI_N65 and EcTopoIII (PDB 1D6M) sequence alignment figure was 
generated with ESPript 3 server (http://espript.ibcp.fr) using multiple protein 







Cloning and Expression of Recombinant SmTopoI 
 
Considering the need to rapidly isolate SmTopoI from host E. coli topoisomerase 
I, cloning into a poly-histidine affinity tag system was chosen and implemented. The S. 
mutans topA gene was first cloned and inserted into the pET15b vector (SmTopA15b), 
introducing a hexa-Histidine (hexa-His) tag at the N-terminus of the target enzyme.123 
The target gene was also cloned or sub-cloned into several alternate vectors in order to 
analyze the effects of different constructs, including affinity tag location and size, as well 
as the usefulness of a protein fusion tag. BL21(DE3)-Gold Competent cells were used for 
the over-expression of target protein. The target gene was also transformed into the 
ArcticExpress Competent Cell system to evaluate the utility of expressing at lower 
temperatures (12oC) in order to increase solubility, but was not found to significantly 
improve results in this instance (data not shown).124,125  
 
Preliminary mini-expression results from the SmTopI15b construct led to a 
traditional IPTG induction and expression that was implemented across all constructs in 
duplicate. Expression products were then carried into initial IMAC nickel column 
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purification trials using a standard linear imidazole elution protocol. While SmTopI16b 
from the N-term deca-His construct and SmTopI-SUMO both significantly outperformed 
the others, SmTopI16b was ultimately selected and carried forward (Table 2-3). Of note, 
as the SmTopI-SUMO enzyme approached the customary 100-kDa E. coli expression 
cutoff, the additional 11 kDa in size added by the SUMO fusion tag showed no apparent 
deleterious effect on the expression in this respective system, demonstrated by the 
average calculated amounts of expressed recombinant protein from the construct trials 
resulting in 88.9 pmol for the ~83 kDa SmTopI16b and 100 pmol for the ~93 kDa 
SmTopI-SUMO, respectively.  
 
As further loss of target protein was anticipated with additional purification steps, 
different conditions were also employed in order to further increase target protein 
expression and convenience, including the implementation of auto-induction for protein 
expression.106 Upon transitioning from a classical IPTG-induction method to a standard 
auto-induction method, the yield of SmTopI16b increased dramatically, as did the 
convenience of the protocol (Table 2-3).106 A subsequent IPTG mini-expression profile 
of SmTopI16b was also conducted in order to determine favorable IPTG expression 
conditions, which was also compared to auto-induced expression and illustrated no 
apparent loss of solubility from adopting an auto-induction method (Figure 2-2).  
 
 
Purification of Recombinant SmTopoI 
 
Early exploratory nickel-nitrilotriacetic acid (Ni2+-NTA) column IMAC 
purification with the pET15b N-term hexa-His tag system showed the affinity of the 
tagged target protein for the Ni2+-NTA column to be markedly weak, leading to both an 
unacceptable loss of target protein during wash steps and very early dissociation upon 
elution. Furthermore, it was discovered upon peptide fingerprinting analysis that what 
was initially presumed to be the ~83 kDa SmTopI15b target protein upon SDS-PAGE 
analysis was actually the ~84 kDa native E. coli catalase HPII protein co-eluting with the 
target protein (Figure 2-3). 
 
Comparative analysis of chromatographic linear elution profiles from the 
SmTopoI IMAC purification trials showed a slight increase in the retention time for the 
deca-His tagged target protein relative to the hexa-His tags (Figure 2-4). Therefore, the 
precise point of elution of SmTopI16b from the linear gradient was observed to be at 
25% elution buffer (about 90 mM imidazole), and this aspect was used to develop a step 
elution protocol. Upon implementation of a 15%, 20%, 100% step elution protocol, 
SmTopI16b eluted in a sharp peak at the 100% elution step and was successfully 
separated from contaminating proteins, including E. coli catalase HPII, as determined by 
SDS-PAGE analysis and His-staining (Figure 2-3). As such, the pET16b N-term deca-
His tag system was deemed the most successful and carried forward for further 
experimentation.  
 
While analyzing mini-expression data, it was determined that target protein 
solubility could likely be improved. A simple transition from 50 mM Tris-HCl pH 8.0 to  
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Growth/Induction Method Overall Yield 
(mg/500 mL)a 
pET-15b N-term 6X His tag 500 mL TB; 0.5 mM IPTG; 
18oC x 24 h 
4.94 (IMAC) 
pET-16b N-term 10X His tag 500 mL TB; 0.5 mM IPTG; 
18oC x 24 h 
7.11 (IMAC) 
6.24 (SE) 
pET-21d C-term 6X His tag 500 mL TB; 0.5 mM IPTG; 
18oC x 24 h 
4.11 (IMAC) 
SUMO N-term SUMO fusion 
tag and N-term 6X His 
tag 
500 mL TB; 0.5 mM IPTG; 
18oC x 24 h 
9.12 (IMAC) 
 
pET-16b N-term 10X His tag 500 mL TB; 0.5 mM IPTG; 
18oC x 24 h; high salt 
8.30 (IMAC) 
pET-16b N-term 10X His tag 500 mL auto-induction media; 




aOverall yields are an average of two 500 mL growths in respective media. 
Reprinted from final submission with permission from Elsevier Inc. Jones, J. A., Price, 
E., Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and 








Figure 2-2. Mini-expression SDS-PAGE. 
 
Mini-expression of SmTopI16b comparing 0.5 mM and 1 mM IPTG induction at 18oC 
over different times as well as auto-induction at 37oC over 24 hours (Sol, soluble 
fraction; Ins, insoluble fraction; AI, auto-induction). Insoluble auto-induction fraction not 
shown as it repeatedly resulted in an unacceptably high amount of smearing, presumed to 
be due to substantial pellet size and an excess of cellular debris.  
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E., 
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and 
purification of bacterial topoisomerase I. Protein Expr Purif 124, 32-40, 





Figure 2-3. Catalase contaminant SDS PAGE. 
 
SDS-PAGE showing initial difficulty presented by native catalase HPII contaminant at 
~84 kDa and target enzyme at ~83 kDa during purification of N-term hexa-His-tagged 
SmTopI_15b construct. Lane 1, ladder; 2-4, nickel column flow-through; 5-7, early 
nickel elution peak; 8-9, middle nickel elution peak; 10-12, tail end shoulder of nickel 
elution peak.  
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E., 
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and 







Figure 2-4. Chromatogram of nickel column linear elution from preliminary 
construct trials.  
 
Direct vertical comparison. (A) N-term hexa-His-tagged SmTopI_15b construct. (B) N-
term deca-His-tagged SmTopI_16b construct. (C) C-term hexa-His-tagged SmTopI_21d 
construct. (D) N-term SUMO and hexa- his-tagged SUMO construct.  
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E., 
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and 





20 mM phosphate buffer pH 7.4 in the lysis and nickel column buffers showed an 
apparent increase in yield and increasing the ionic strength of the nickel column binding 
and wash buffers (from 150 mM to 1 M NaCl) and the nickel column elution buffer (from 
150 mM to 500 mM NaCl) greatly increased the overall purification yield of SmTopI16b 
(Table 2-3 and Figure 2-5). A long wash step over 40 CVs with the higher ionic strength 
binding buffer also resulted in satisfactory removal of DNA from the target protein. 
Absorbance at 260 nm and 280 nm was monitored, ensuring the maximal removal of 
DNA. As stated above, transitioning to an auto-induction expression protocol also 
significantly improved yield and convenience.  
 
Following successful IMAC purification, SmTopI16b was identified upon SDS-
PAGE analysis as an overexpressed band (Figure 2-5a). Target protein identity was 
confirmed initially using mass spectrometry peptide fingerprinting (Figure 2-6), 
secondarily upon His-epitope tag antibody directed western blot (data not shown), and 
again using His-tag staining (Figure 2-5b). Protein concentrations and yield were 
calculated using the standard Bradford protein assay with BSA as the protein standard, 
which is compatible with the IMAC elution buffer.126  
 
Following optimization of the IMAC purification step, analyses with several 
alternative secondary purification methods, including the use of a heparin column, cation 
and anion exchange columns, a Cibacron Blue column, and a size exclusion (SE) column 
were conducted. Ultimately, transitioning straight from IMAC to a second, polishing size 
exclusion step was chosen due to simplicity and the fact that it showed the overall 
greatest yield. The target protein size of ~83 kDa was judged to be distinct enough from 
any of the remaining ~97 kDa native E. coli topoisomerase I to separate them using size 
exclusion chromatography. After increasing the ionic strength of the size exclusion buffer 
(from 150 mM NaCl to 500 mM NaCl), the target protein solubility was found to be 
sufficient for purification without the need for an intermediate buffer exchange or dialysis 
step of the Ni2+-NTA purification product, which again afforded an additional gain in 
speed and convenience. Following the size exclusion chromatography polishing step, the 
target protein was collected and again analyzed via SDS-PAGE, indicating purity deemed 
greater than 95%. Yield was again determined from duplicate trials by Bradford protein 
assay with BSA as a standard, which indicated over 23 mg/L of target protein (Table 2-3 
and Table 2-4). 
 
 
Characterization of SmTopoI 
  
In order to track protein activity, a gel-based DNA-relaxation assay was employed 
using published methods (Figure 2-7).104 The activity of SmTopI16b was maintained 
over three months in SE Buffer 2 refrigerated at 4oC, as well as after overnight freeze 
trials at -80oC including enzyme with and without 50% glycerol using both snap-freezing 
and drop-wise freezing methods in liquid nitrogen (Figure 2-8). Protein activity after 
cleavage of the deca-His tag was also analyzed, showing no apparent increase in activity 





Figure 2-5. SDS-PAGE gels of SmTopI_16b purification results.  
 
(A) SDS-PAGE after blue-staining. (B) SDS-PAGE after His-staining in order to verify 
target protein bands. L, ladder; CE, clarified extract from auto-induction growth; FT, 
nickel column flow-through; P1, nickel column first peak from first step elution using 
high salt buffers; Ni2+, target fraction from nickel column; SE, target fraction from size 
exclusion; Ec; commercially available E. coli topoisomerase I; TB, target fraction from 
nickel column from TB growth with high salt buffers.  
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E., 
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and 







Figure 2-6. Peptide fingerprinting.  
 
Peptide fingerprinting analysis showing 74.20% sequence coverage for Topoisomerase I 
from Streptococcus mutans serotype c (strain ATCC 700610/UA159).  
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E., 
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and 
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23.3 22.6 58,250 2,575 21 97 
 
a Protein concentration determined by Bradford assay using BSA as the standard protein. 
b Amount of target protein determined based off of SDS-PAGE gel analysis. 
c Activity measured as described under Materials and Methods section. 
d Purity determined based off of SDS-PAGE gel analysis. 
Reprinted from final submission with permission from Elsevier Inc. Jones, J. A., Price, 
E., Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and 







Figure 2-7. Gel-based DNA relaxation assay. 
 
Lane 1, ladder; lane 2, supercoiled pUC18 plasmid (DNA substrate as negative control); 
lane 3, commercially available E. coli topoisomerase I (positive control); lanes 4-10, 
SmTopI16b enzyme in increasing concentration (nM). N, nicked; FR, fully relaxed; PR, 
partially relaxed; SC, supercoiled.  
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E., 
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and 










Figure 2-8. SmTopI16b freeze trials. 
 
Agarose gel showing activity of target enzyme frozen via different methods (1 ug enzyme 
used, except 400ng used for [low] samples and 1 unit for EcTopoI positive control). 
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E., 
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and 







Figure 2-9. His-tag cleavage activity assay.  
Agarose gel showing activity of SmTopI16b after cleavage of deca-his tag via factor Xa. 
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E., 
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and 
purification of bacterial topoisomerase I. Protein Expr Purif 124, 32-40, 
https://dx.doi.org/10.1016%2Fj.pep.2016.04.010. (2016).73  
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implementation of a non-specific DNase activity assay using published methods (Figure 
2-10).103  
  
To characterize the stability of SmTopI16b, a number of methods were employed. 
Hampton Research Solubility & Stability Screen 2™ was used to assess conditions that 
mitigate target protein precipitation and increase its overall stability.127 Optimal buffer 
conditions as determined via Differential Scanning Fluorimetry (DSF, or “thermal shift”) 
from the screen were found to be 0.05 M sodium citrate tribasic dihydrate (pH 5.0) with 
4.0 M sodium chloride as showcased by an optimal melting temperature (Tm) of 48oC 
(Figure 2-11).  An apparent trend was seen showing optimal buffer conditions included 
relatively low pH and high salt content. Protein solubility was also analyzed via overnight 
dialysis trials into lower-salt-containing buffers across a wide range of pH values. Results 
showed considerable visual precipitation regardless of buffer and pH when ionic strength 
was decreased below 200 mM NaCl with protein concentration at 1 mg/mL, indicating 
the necessity of a higher ionic strength buffer for the solubility of this particular enzyme 
and construct (data not shown).  
 
 
Crystallization of SmTopoI_N65 
 
As reported previously, soluble full-length SmTopoI did not initially express well 
and, even after expression was optimized, its solubility required extremely high salt 
conditions not generally conducive to crystallization.73 As such, full-length SmTopoI 
proved recalcitrant to crystallization. Eventually, the C-terminal domain was rationally 
removed for subsequent crystallization trials. Iteratively shorter N-terminal fragment 
SmTopoI constructs corresponding to the original 67-kDa N-terminal EcTopoI 
(EcTopoI_N67) crystal structure (PDB 1ECL)99,100 were cloned, expressed, purified, and 
screened for crystals. After multiple fragments were screened, this eventually proved 
successful as diffraction-quality crystals of the 65-kDa 575 residue SmTopoI fragment 
were attained, however the diffraction resolution was relatively low (greater than 4 Å). 
Upon fine grid screening and implementation of temperature trials, high-resolution 




Overall Structure of SmTopoI_N65 
 
The three-dimensional crystal structure of SmTopoI_N65 was determined to 2.06 
Å via molecular replacement using the EcTopoI_N67 crystal structure (PDB 1ECL) as a 
model,99,100 followed by iterative cycles of model building and refinement (Table 2-5). A 
sequence alignment between SmTopoI_N65 and EcTopoI_N67, which share a 42.9% 
sequence identity, is shown (Figure 2-13). The root mean square deviation (RMSD) 
between the two structures is 1.83Å. Analysis of the crystal structure and Matthews 
Coefficient indicate that there is one monomeric SmTopoI_N65 molecule per asymmetric 
unit (Figure 2-14).128-130 The monomeric state of SmTopoI_N65 was further 





Figure 2-10. Non-Specific DNase Activity Assay. 
 
Agarose gel confirming a lack of DNase activity after 6 hours incubation.  
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E., 
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and 








Figure 2-11. Thermal stability data.  
 
Data showing differing thermal stability profiles of SmTopI16b with different salts and 
buffers.  
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E., 
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and 








Figure 2-12 SmTopoI_N65 crystals. 
 
A. Original SmTopoI_N65 crystals grown at 18°C from coarse JCSG plus screen, 
condition 1-5 (0.2 M magnesium formate dihydrate and 20% PEG 3350). B. Same crystal 
as in (A), but stained with a 1:1 mixture of Izit Crystal Dye (Hampton Research, Aliso 
Viejo, CA) and acid red dye. C. Optimized SmTopoI_N65 crystal grown in 0.2 M 
magnesium formate dihydrate and 25% PEG 3350 at 4°C used for structure 
determination.  
Reprinted from final submission with open access permission, Elsevier, Inc. Jones, J. A. 
& Hevener, K. E. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA 
topoisomerase I from the gram-positive model organism Streptococcus mutans. Biochem 





Table 2-5. Data collection and refinement statistics for SmTopo_N65. 
 
Data Collection Results 
Wavelength (Å) 1.033 
Space Group P 21 21 2 
Unit cell parameters  
a, b, c (Å) 88.58 98.37 72.71 
, ,  (°) 90 90 90 
Resolution (Å) 50.00 - 2.06 (2.10 - 2.06)a 
CC1/2 0.999 (0.690) 
Rmeas 0.084 (1.047) 
Rpim 0.032 (0.441) 
Total no. of reflections 254919 
No. of unique reflections 32714 (1394) 
Completeness (%) 82.17 (35.50) 
Redundancy 6.5 (5.1) 
Mean I/sigma 21.8 (1.5) 
Refinement 
Number of reflections used 32713 (1395) 
Resolution (Å) 49.18  - 2.063 (2.137  - 2.063) 
Rwork 0.2003 (0.2310) 
Rfree 0.2677 (0.3617) 




Protein residues 538 
RMS (bonds) 0.008 
RMS (angles) 0.92 
Ramachandran favored (%) 96.24 
Ramachandran allowed (%) 3.20 
Ramachandran outliers (%) 0.56 
Rotamer outliers (%) 0.42 
Clash score 4.98 





a Statistics for the highest-resolution shell are shown in parentheses. 
CC1/2 is the Pearson’s correlation coefficient of random half sets of data.  
Adapted from final submission with open access permission from Elsevier Inc. Jones, J. 
A. & Hevener, K. E. Crystal structure of the 65-kilodalton amino-terminal fragment of 
DNA topoisomerase I from the gram-positive model organism Streptococcus mutans. 






Figure 2-13. Multiple sequence alignment of SmTopoI_N65 and structural 
homologs. 
 
Comparison of SmTopoI_N65, EcTopoI_N67, and MtTopoI via multiple sequence 
alignment shows high degree of sequence identity and similarity, including the highly 
conserved active site. Identical residues are highlighted in red, similar residues are 
highlighted in yellow, catalytic tyrosine is indicated with a red dot, active site residues 
within 5 Å from catalytic tyrosine are indicated with blue dots, and the nine-residue loop 
extension seen in SmTopoI_N65 is indicated with a magenta bar.98,99,118  
Reprinted from final submission with open access permission, Elsevier, Inc. Jones, J. A. 
& Hevener, K. E. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA 
topoisomerase I from the gram-positive model organism Streptococcus mutans. Biochem 





Figure 2-14. Overall structure of SmTopoI_N65  
 
A. Flat ribbon diagram of the overall structure of SmTopoI_N65 showcasing the four N-
terminal domains that comprise the main body. D1, D2, D3, and D4 are colored in blue, 
orange, yellow, and green, respectively. Sub-domain secondary structures are also 
numbered respectively. The unique loop extension before and immediately adjacent to 
the active site in D3 between α2 and α3 is colored magenta. The small outcropping from 
D1 that is considered a part of D4 as in the EcTopoI and MtTopoI structures is colored 
charcoal. The catalytic Y316 residue in D3 is drawn in stick and colored red.  B. Mesh 
surface diagram of SmTopoI_N65 with the same color and orientation as in A, but turned 
on x axis by -10° for improved view of DNA binding site and groove, shown as a red 
arrow, with accompanying 90° turn along the y axis for profile view. C. Coulombic 
surface coloring showing electrostatic potential with standard red/negative and 
blue/positive coloring in the same orientation as B. The DNA binding site and groove is 
also shown with a red arrow. D. Structural alignment of SmTopoI_N65 with 
EcTopoI_N67 (1ECL) and MtTopoI.118  
Reprinted from final submission with open access permission, Elsevier Inc. Jones, J. A. 
& Hevener, K. E. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA 
topoisomerase I from the gram-positive model organism Streptococcus mutans. Biochem 





Electron density of the hexa-histidine tag is not visible in the model, nor is density for the 
first leading 18 N-terminal residue peptide chain (M1 to T18), which exists as an 
additional N-term extension compared to EcTopoI, similar to the first 16 residues seen in 
MtTopoI (PDB 5UJ1).95 This unmodeled N-term peptide continues to be of unknown 
function. It carries substantial positive charge and is relatively polar, with five positively 
charged lysines and one positively charged arginine, as well as six polar uncharged 
threonines and two polar uncharged serines. The SmTopoI_N65 model begins at P19, 
with K21 of SmTopoI_N65 aligning with K3 of EcTopoI_N67. This represents the 
beginning of the highly conserved topoisomerase-primase (TOPRIM) domain, which 
ends at N129 and N140 of SmTopoI_N65 and EcTopoI_N67, respectively.132 
 
The SmTopoI_N65 model includes the first four domains of the overall structure, 
which comprise the main body core and show an intricate topology (Figure 2-14 and 
Figure 2-15).133 Domains D1, D3, and D4 form the base of the body, and D2 forms the 
bulk of the toroid arch that represents the hinge domain. D1 is comprised of four alpha 
helices and three beta strands. D2 is connected to D4 via a bridge of two flexible loops 
and is comprised overall of two alpha helices and six beta strands. D3 is comprised of 
five alpha helices, with a likelihood of α4 actually forming a 310 helix. The catalytic 
Y316 residue is also located within D3 on a loop between α2 and α3 at the interface of 
D1, D3, and D4. The remainder of the highly conserved active site surrounds the catalytic 
tyrosine residue.  
 
While the SmTopoI_N65 fragment shares 42.9% sequence identity with the 
EcTopoI_N67 sequence and 25.19% sequence identity with the EcTopoIII sequence 
(PDB 1D6M, Figure 2-16), full-length SmTopoI shares 41.4% identity with full-length 
EcTopoI and 25.3% with full-length E. coli topo III, 37.1% identity with full-length 
MtTopoI, and 42.8% identity with full-length topo I from the thermophile T. maritima 
(TmTopoI).120 Of note, full-length SmTopoI shares 61.9% identity with the topo I 
enzyme from Staphylococcus aureus (SaTopoI), for which there is currently no 






Expression and Purification of SmTopoI 
 
An active full-length bacterial topoisomerase I enzyme has been purified to a 
relatively high yield and purity from the clinically relevant bacteria S. mutans. A 
systematic analysis of different protein constructs was necessary as an unacceptable 
amount of the prototype hexa-his tagged protein showed weak affinity for the nickel 
column and was therefore lost to flow-through and overly contaminated with early co-
eluting proteins. In order to analyze the possibility of the obstruction of the N-term His 
tag in the protein’s folded state, the target gene was cloned into a pET21d vector 
(SmTopA21d), placing a hexa-His tag at the C-terminus. As increasing the length of 





Figure 2-15. SmTopoI_N65 topology diagram. 
 
Topology diagram of SmTopoI_N65 created with PDBsum showing beta strands as pink 
arrows and alpha helices as red cylinders.121  
Reprinted from final submission with open access permission, Elsevier Inc. Jones, J. A. 
& Hevener, K. E. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA 
topoisomerase I from the gram-positive model organism Streptococcus mutans. Biochem 








Figure 2-16. Multiple sequence alignment of SmTopoI_N65 and EcTopoIII. 
 
Comparison of SmTopoI_N65, EcTopoIII (PDB 1D6M) via multiple sequence alignment 
shows moderate sequence identity and similarity, with high sequence identity between 
the highly conserved active sites. Identical residues are highlighted in red, similar 
residues are highlighted in yellow, catalytic tyrosine is indicated with a red dot, active 
site residues within 5 Å from catalytic tyrosine are indicated with blue dots, and the nine-
residue loop extension seen in SmTopoI_N65 is indicated with a magenta bar.119,122 
Reprinted from final submission with open access permission, Elsevier Inc. Jones, J. A. 
& Hevener, K. E. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA 
topoisomerase I from the gram-positive model organism Streptococcus mutans. Biochem 




more rigorous wash steps, and generally resulting in improved removal of non-specific 
binding contaminant proteins, this concept was also explored by sub-cloning the target 
gene from the pET15b vector into a pET16b vector, placing and extended deca-His tag at 
the N-terminus.134,135 Finally, as the small ubiquitin-related modifier (SUMO) fusion 
system has been reported to increase both target protein solubility and target protein 
expression levels, the target was cloned into the pET SUMO vector system (SmTopA-
SUMO) in order to analyze the usefulness of an N-term SUMO fusion protein along with 
an N-term hexa-His tag.136,137  
 
Of the various constructs examined, the product of the deca-his-tagged pET16b 
construct (SmTopI16b) resulted in enough of an apparent increase in affinity for the 
nickel column to be successfully exploited via a step-wise elution to satisfactorily isolate 
the tagged target protein from the co-eluting contaminant proteins that plagued the hexa-
his-tagged pET15b construct. Furthermore, enzyme activity was maintained with the 
deca-his-tagged construct, bypassing the immediate need for cleaving the affinity tag for 
downstream applications—a luxury not necessarily expected with the larger SUMO 
fusion tag construct (which also showed promising results in the purification trials).  
 
Because the separation of DNA from DNA-binding proteins like topoisomerase I 
is essential, yet particularly onerous, a protocol implementing a rapid and efficient means 
of addressing this obstacle was highly desired. As an alternative to more traditional DNA 
removal methods, the ionic strength of the buffers used in the IMAC purification step 
were increased and the Ni2+-NTA-bound target protein was exposed to a high salt wash 
over an extended period of time in order to successfully disrupt the largely electrostatic 
nature of DNA-protein binding.138 Therefore, in order to further optimize SmTopI16b 
yield, higher ionic strength buffers were employed to both increase the solubility of the 
target protein as well as to aid in the expedited removal of DNA during purification steps. 
Additionally, auto-induction was successfully adopted in order to increase yield and 
greatly decrease the effort required during the expression and purification protocol. As 
mini-expression analysis showed no apparent gain or loss in target solubility by adopting 
auto-induction, it was deduced that the overall increase in target protein yield seen 
between auto-induction and IPTG-induction likely resulted from greater overall growth.  
 
 
Unique structural features of SmTopoI_N65 
 
The SmTopoI_N65 model shows only 3 beta strands in D1, whereas EcTopoI and 
MtTopoI each contain four D1 beta strands. Within 5 Å from the catalytic center of 
Y316, only one dissimilar residue is observed between SmTopoI_N65 and 
EcTopoI_N67, found between the two aspartates on the DXD TOPRIM motif—that is, 
P101 on SmTopoI_N65, versus L112 on EcTopoI_N67. Interestingly, immediately prior 
to the conserved active site, SmTopo_N65 displays a unique nine residue loop extension 
(Figure 2-13 and Figure 2-14) not present in any of the topo I structures previously 
determined, except for a similar but non-identical extension seen in topo I from the 
extremophile Thermotoga maritima (PDB 2GAI; Figure 2-17). The SmTopoI_N65 loop 





Figure 2-17. Structural alignment of SmTopoI_N65 and TmTopoI (PDB 2GUI) 
 
Structural alignment of SmTopoI_N65 (red) with topo I from the thermophile 
Thermotoga maritima, TmTopoI (PDB 2GUI; green) shown in flat ribbon format 
conducted with UCSF Chimera MatchMaker structure comparison tool.95,113 The unique 
loop extension near the active site is highlighted with a red circle and the catalytic Y316 
residue on SmTopoI_N65 if shown in stick format.  
Reprinted from final submission with open access permission, Elsevier, Inc. ones, J. A. & 
Hevener, K. E. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA 
topoisomerase I from the gram-positive model organism Streptococcus mutans. Biochem 
Biophys Res Commun, https://doi.org/10.1016/j.bbrc.2019.06.034 (2019. In Press).74  
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Further sequence alignment analysis of SmTopoI_N65 against several additional select 
bacteria shows an intriguing lack of this nine-residue extension in several prominent gut 
microbes, such as E. coli, Bacteroides ovatus, Bacteroides fragilis, and Bifidobacterium 
breve, while a similar extension exists not only in the thermophile T. maritima, but also 
in Staphylococcus aureus, Clostridioides difficile, and Neisseria gonorrhoeae (Figure  
2-18). Lastly, as seen in MtTopoI, but dissimilar to EcTopoI_N67, SmTopoI_N65 lacks 





As a DNA binding enzyme, SmTopoI presents inherent difficulties during 
expression and purification. Nonetheless, an effective, rapid, and simplified protocol was 
developed for the high-yield expression and purification of bacterial topoisomerase I at 
over 23 mg/L estimated at greater than 95% yield via SDS-PAGE analysis. With such a 
substantial yield of active and highly pure full-length SmTopoI enzyme, the enzyme can 
be used for effective biochemical and biophysical techniques that will allow for further 
target characterization and validation studies, as well as future compound screening 
campaigns and kinetic studies. Due to a number of circumstances, the full-length enzyme 
is unfortunately not well-suited for a variety of structural studies. As the enzyme is 
roughly 83 kDa, it is both too small for cryo-electron microscopy and too large for NMR. 
Additionally, what is presumed to be the highly dynamic nature of the full-length enzyme 
and the requisite high levels of salt necessary to maintain stability, it is also not well-
suited for X-ray crystallography.  
 
Via rational construction of a shortened construct of SmTopoI, useful structural 
information has nonetheless been attained from SmTopoI_N65 crystal structure 
determination. Because of the inherently conserved nature of topo I, SmTopoI_N65 
exhibits a substantial degree of sequence identity and similarity with other previously 
determined topo I structures, including a highly conserved active site and similar overall 
structure. Therefore, any novel distinction among topo I homologues is likely of 
significant interest and, as such, the SmTopoI_N65 nine-residue extension located 
immediately N-term-adjacent to the active site is notably unique as this extension is not 
seen in topo I structures from either E. coli or M. tuberculosis. What may have gone 
previously overlooked as an insignificant structural variation in topo I from an 
extremophile inconsequential to human health (TmTopoI), the presence of this loop 
extension in S. mutans—a bacterium noted for both its utility in research as a Gram-
positive model organism and its significance in dental and cardiovascular health—stands 
as a structural dissimilarity that certainly draws attention and may warrant further 
analysis. Its proximity to the enzyme active site is indeed intriguing, and important 
questions regarding any underlying significance, including possible implications related 
to enzymatic efficiency, target DNA sequence selectivity or stabilization, or even the 
possibility of rationally designing selective catalytic topo I inhibitors that exploit partial 




Figure 2-18. SmTopoI_N65 multiple sequence alignment with select topo I 
homologs of undetermined structure. 
 
Comparison of SmTopoI_N65 with homologs from various select bacteria, including E. 
coli, M. tuberculosis, T. maritima, S. aureus, C. difficile, N. gonorrhoeae, B. ovatus, B. 
fragilis, and B. breve via multiple sequence alignment. Sequence alignment was 
generated with the ESPript 3 server (http://espript.ibcp.fr/) using a multiple protein 
sequence alignment produced with Clustal Omega, with secondary structure information 
extracted from the SmTopoI_N65 structure.89,93,95,114,115 Alignment shows high degree of 
sequence identity and similarity, including the highly conserved active site. Identical 
residues are highlighted in red, similar residues are highlighted in yellow, catalytic 
tyrosine is indicated with a red dot, active site residues within 5 Å from catalytic tyrosine 
are indicated with blue dots, and the nine residue loop extension seen in SmTopoI_N65 is 
indicated with a magenta bar.119,122  
Reprinted from final submission with open access permission, Elsevier, Inc. Jones, J. A. 
& Hevener, K. E. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA 
topoisomerase I from the gram-positive model organism Streptococcus mutans. Biochem 















Employing X-ray crystallographic methods, this work identified conditions 
producing crystals that diffracted to 2.06 Å resolution, resulting in the first determined 
topo I structure from a Gram-positive bacterium, SmTopoI_N65. This topo I fragment 
structure offers important insight into both the similarities and differences between 
bacterial topo I from several different relevant organisms. Continued efforts to 
characterize SmTopoI are still warranted, including but not limited to the structural 
determination of full-length SmTopoI, co-crystal structures with bound oligonucleotides, 
enzymatic and kinetic studies, as well as various studies focused on the relatively unique 
active-site-adjacent nine-residue loop extension highlighted in this work. Such studies 
regarding the latter topic may include studies deleting, extending, or mutating the loop 
itself, as well as side-by-side comparison of structural and enzymatic studies of topo I 
enzymes from various bacterial organisms, including those with and without the loop 
extension. Nonetheless, the results of these studies have improved our knowledge of topo 





CHAPTER 3.    TARGETING ACYL CARRIER PROTEIN (ACP)-ENOYL 









Clostridioides difficile (formerly Clostridium difficile) is a gram-positive, spore-
forming, anaerobic pathogen that is the leading cause of health care-associated diarrhea 
and gastroenteritis-associated deaths in the U.S.139-142 Clinical consequences of C. 
difficile infection (CDI) range from asymptomatic or mild diarrhea to recalcitrant 
diarrhea and fatal pseudomembranous colitis.143 CDI is caused by the eradication of key 
gut flora, such as Bifidobacterium sp. and Bacteroides sp., which normally suppress C. 
difficile overgrowth.144 This typically occurs via the use of broad-spectrum antibiotics 
(e.g., clindamycin, fluoroquinolones, and beta-lactams).144-146 The first-line CDI 
treatment, vancomycin, exhibits activity against beneficial gut flora and results in their 
eradication, contributing to high rates of recurrence.147,148 Further contributing to relapse 
is the pathogen’s ability to produce treatment-resistant spores that survive in the intestinal 
tract.149,150 The emergence of epidemic strains, namely BI/NAP1/027 (North American 
pulsed-field gel electrophoresis type 1, ribotype 027), correlated with an increase in 
incidence and severity of CDI.147 While the alternative first-line drug fidaxomicin is 
narrow-spectrum and reduces recurrence, it has failed to show evidence of doing so in 
NAP1-mediated infections.151,152 Fecal microbiota transplantation (FMT) shows promise, 
but long-term safety data is still lacking, including non-infectious microbiota-related 
metabolic diseases like obesity.153,154 While new agents are currently in clinical trials, 
recent failures highlight the pressing need for novel anti-CDI agents to maintain the 
discovery pipeline.146,155 These issues emphasize that C. difficile remains a high-priority 
candidate for the development of novel narrow-spectrum antibacterial agents.  
 
 
Bacterial Type II Fatty Acid Biosynthesis (FAS II) Pathway 
 
During cyclic fatty acid elongation within the bacterial type II fatty-acid synthesis 
(FAS II) pathway, enoyl-acyl carrier protein (ACP) reductase enzymes catalyze the 
critical, rate-limiting terminal reduction step. The FAS-II system provides fatty acid 
precursory components vital to bacterial organisms for various biological processes like 
membrane phospholipid production and sporulation.156 Strong scientific precedent 
substantiates these enzymes as antimicrobial drug targets, exemplified by isoniazid, a 
                                                 
 
3 Portions of chapter from final submission adapted with permission from Jones, J. A.* et al. Small-
molecule inhibition of the C. difficile FAS-II enzyme, FabK, results in selective activity. ACS Chem Biol, 
https://doi.org/10.1021/acschembio.9b00293 (2019. In Press). (*Co-first author.) Copyright (2019) 
American Chemical Society.139 
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marketed inhibitor of tubercular InhA (enoyl-ACP reductase); triclosan, a well-known 
antibacterial FabI inhibitor; and the anti-staphylococcal FabI inhibitor afabicin (Debio-
1450) currently in clinical trials.31,157-159 While the existence of four distinct enoyl 
reductase isozymes (FabI, FabK, FabL, and FabV) in bacteria precludes the development 
of broad-spectrum antibacterials targeting them, it affords an ideal opportunity for the 
rational design of narrow-spectrum agents.68-70 Bioinformatics analyses of sequenced C. 
difficile genomes indicate it expresses the FabK isozyme as its sole enoyl-ACP 
reductase.67,160  
 
FabK, a member of the triosephosphate isomerase (TIM) barrel family of 
proteins, is a less abundant isozyme among the four enoyl-ACP reductases, and lacks 
sequence similarity to FabI, FabL, and FabV, which are members of the short-chain 
alcohol dehydrogenase/reductase (SDR) superfamily.69,161 Like the other isozymes, FabK 
requires either NADH or NADPH as a cofactor for activity, but unlike its SDR 
counterparts, FabK is a flavoenzyme that utilizes flavin mononucleotide (FMN) as an 
active site prosthetic group. FabK is also unique in that it uses a bi-bi double 
displacement (ping-pong) enzymatic mechanism for reducing its enoyl substrate.69,161-168 
The SDR enzymes, however, possess a classical Rossman fold for binding their 
NAD(P)H cofactor and rely on an ordered sequential enzyme mechanism for reducing 
their enoyl substrates.169,170 While there has been recent debate about the essentiality of 
the FAS-II pathway in Gram-positive bacteria,171-173 several groups have shown that 
possession of the FapR regulatory system over FabT, as seen in S. aureus, prevents full 
bypass of FAS-II inhibition by exogenous fatty acid uptake.71,72 Indeed, it was recently 
showed that C. difficile, which also possesses FapR, behaves in a similar manner as 
exogenous fatty acids were unable to rescue the pathogen from FAS-II inhibition.67 C. 
difficile also has unique branched fatty acid requirements, further limiting the likelihood 
of escape from FAS-II inhibition.174,175 Recent work also demonstrated the ability of 
FAS-II inhibition to decrease spore formation by nearly 90%, which in principle could 
reduce potential for spore survival, associated endogenous recurrence, and spore 
dissemination.67   
 
 
FabK as a Narrow-spectrum Target 
 
CDI pharmacotherapy has shown that maximizing therapeutic success includes 
preventing collateral damage to the GI microbiome. Important gut species such as Gram-
negative Bacteroides sp.176 express FabI with or without FabK, while Bifidobacterium sp. 
lack FabK entirely.67 Importantly, published FabK inhibitors are inactive against FabI 
and FabI-bearing strains.164,167 Similarly, FabK has demonstrated resistance to FabI 
inhibitors like triclosan, which are consequently inactive against strains carrying 
FabK.69,162,177,178 Lastly, the ability of bacterial strains carrying two enoyl reductases to 
survive the deletion of one isozyme suggests that both enzymes would need to be dually 
inactivated to inhibit the growth of such organisms.68 This data justifies the investigation 
of FabK as a narrow-spectrum target for selective anti-difficile therapy. In an effort to 
initially characterize the enzyme target, the following research includes CdFabK 
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expression and purification details, preliminary CdFabK characterization, and continuing 






Protein Expression, Purification, and Stabilization of CdFabK 
 
 In order to carry out the desired enzyme target characterization and validation, a 
high yield of high purity CdFabK was required. Because previous attempts had resulted 
in low yields of inactive enzyme, a number of different purification methods were tested 
to maximize the chances of success. As perhaps the most popular initial protein 
purification is IMAC, this was attempted with various hexa-histidine tag placements, 
including N-terminal and C-terminal tags. Additionally, native CdFabK was expressed 
and purified as tag placement has been reported to impede both enzyme activity and 
crystallization.179  
 
 While high quantity and purity of produced target enzyme is indeed of great 
importance, the desire to develop assays for the screening of inhibitory compounds and to 
characterize any potential compounds required the need for active and stable compounds. 
As such, iterative and systematic trials were necessary for determining optimized storage, 
assay, and crystallization conditions. Herein, the high-yield expression, rapid two-step 
purification, and stable enzyme activity conditions of FabK from C.difficile is reported. 
Production methods and can be carried out in a single day with an estimated purity of 
95% or higher.  
 
 
Crystallization of CdFabK 
 
 As the three-dimensional structure of CdFabK has not been previously 
determined, a high resolution structure of CdFabK is required in order to conduct 
structural characterization and structure-guided drug discovery efforts. As stated earlier, 
the CdFabK enzyme is too small for cryo-EM studies and too large for NMR structural 
studies. Therefore, X-ray crystallography is, by default, necessary for such requisite 
structural determination and analyses. In order to crystallize CdFabK, a variety of coarse 
crystallization screens for apo- and co-crystal CdFabK structures were carried out, and 
subsequent fine screening trials were also conducted. Herein, the conditions for the 





Materials and Methods 
 
 
CdFabK Construct Cloning, Plasmid Production, and Expression 
 
The fabk gene from C. difficile strain 630 was commercially optimized, 
synthesized, and cloned into the pET15b vector by GenScript (Piscataway, NJ) carrying 
an N-terminal hexa-histidine tag.139 The gene was also cloned into the pET21d vector 
with two different constructs, one carrying a C-term hexa-histidine tag, and the other 
carrying no tag and encoding only the native enzyme as the gene of interest. The 
respective plasmid products (CdFabK_15b, CdFabK_21d, and CdFabK_21d_NATIVE, 
respectively) were then transformed into XL1-Blue Supercompetent cells (Agilent 
Technologies, Santa Clara, CA) per protocol. Upon successful transformation, the 
plasmids were then isolated with the QIAprep Spin Miniprep Kit via protocol and the 
sequences were confirmed via the University of Tennessee Health Science Center 
(UTHSC) Molecular Research Center (MRC) sequencing services (Memphis, TN). After 
sequence confirmation, the plasmids were also transformed into BL21(DE3)-Gold 
Competent cells (Agilent Technologies, Santa Clara, CA) via protocol.  
 
The proteins were overexpressed in E. coli BL21(DE3)-Gold Competent cells 
(Agilent Technologies, Santa Clara, CA) cultivated at 37°C in TB medium with 100 
g/mL ampicillin by transferring 1% (v/v) overnight culture into fresh medium. Cells 
were allowed to grow until they reached an OD600 of ~ 0.6 and the protein expression was 
induced with 0.1 mM IPTG supplemented with 0.5 mM flavin mononucleotide (FMN). 
Growth temperature was decreased to 18C and cells were allowed to grow further for 18 
hours at 18C. After induction and growth, the cells were harvested by centrifugation at 
18000 x g for 15 minutes. Pellets were stored at -80C until use. 
 
 
CdFabK_15b and CdFabK_21d Purification 
 
Pellets were resuspended in CFabK Buffer A (20 mM HEPES buffer pH 8.0 with 
300 mM NH4Cl, 1 mM DTT, 18% glycerol, 10 g/mL benzamidine, and 10 mM 
imidazole). Lysis components were then added, including 0.5 mg/mL lysozyme, 10 
µg/mL DNaseI, 5 mM MgCl2, 0.5% Triton-X 100, 25 mM sucrose, and 1 Pierce® 
EDTA-free Protease inhibitor tablet per 50 mL. Cells were lysed at 4°C with gentle 
stirring, then sonicated at 50% amplitude on ice for eight minutes with eight seconds on 
and 24 seconds off. Lysates were centrifuged at 39,000  g for 15 minutes and the 
supernatants were filtered through a 0.22 polyethersulfone (PES) syringe filter (EMD 
Millipore, Billerica, MA).  
 
His-tagged proteins were purified via immobilized metal affinity chromatography 
(IMAC) by loading the filtered lysate on a HisTrap HP column (GE Life Sciences) in 
CdFabK Buffer A, washed over 20 column volumes with CdFabK Buffer A, and eluted 
via linear gradient to 100% CdFabK Buffer B (CdFabK Buffer A with 500 mM 
imidazole) over 20 column volumes. Peak eluted proteins were pooled and further 
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purified by SEC on a HiLoad 26/600 Superdex 200 PG size exclusion column (GE 
Healthcare Life Sciences, Pittsburgh, PA) in CdFabK SEC Buffer (50 mM HEPES pH 
8.0, 300 mM NH4Cl, 18% glycerol, and 3 mM DTT) via isocratic elution. After 
purification, proteins were concentrated via 10,000 MWCO Amicon™ Ultra-15 
Centrifugal Filter Units and brought to 100 M with 38.5% glycerol, snap frozen in 
liquid nitrogen, and stored at -80°C until future use. Proteins have been confirmed active 
up to six months after storage under these conditions. Enzyme was confirmed via SDS-
PAGE gel analysis (Mini-PROTEAN® TGX Stain-Free™ Pre-Cast Gel and Precision 
Plus Protein™ Unstained Standard, Bio-Rad Laboratories, Hercules, CA) and the enzyme 
activity was analyzed in an Implen NP80 nanophotometer as described below (West Lake 
Village, CA). Enzyme concentration was determined via PierceTM 660nm Protein Assay 





Pellets were resuspended in Anion Buffer A (20 mM BIS TRIS Propane buffer 
pH 9.5, 1 mM DTT, and 18% glycerol). Lysis components were then added, including 
0.5 mg/mL lysozyme, 10 µg/mL DNaseI, 0.5% Triton-X 100, and 1 Pierce® EDTA-free 
Protease inhibitor tablet per 50 mL. Cells were lysed at 4°C with gentle stirring, then 
sonicated at 50% amplitude for eight minutes with eight seconds on and 24 seconds off. 
Lysates were centrifuged at 39,000  g for 15 minutes and the supernatants were filtered 
through a 0.22 PES syringe filter (EMD Millipore, Billerica, MA).  
 
Native CdFabK protein (CdFabK_NATIVE) was purified via anion exchange 
chromatography by loading the filtered lysate on HiTrap Q HP GE Column (GE Life 
Sciences) in Anion Buffer A, subsequently washed with 20 column volumes with Anion 
Buffer A, and then eluted via linear gradient to 100% Anion Buffer B (Anion Buffer A 
with 500 mM NH4Cl) over 20 column volumes. The 450 nm wavelength was followed to 
discern fractions containing FabK cofactor, flavin mononucleotide (FMN), which was 
followed to track the presence of the CdFabK_NATIVE protein. Fractions were collected 
and pooled, enzyme was confirmed via PAGE gel analysis, and the enzyme activity was 
analyzed in an Implen NP80 nanophotometer as described below (West Lake Village, 
CA). Enzyme concentration was determined via PierceTM 660nm Protein Assay Reagent 
(ThermoFisher Scientific (Waltham, MA, USA) per protocol. 
 
 




All activity and stability assays were carried out at 25°C. Trials were conducted in 
the presence of 50 nM CdFabK_15b N-term hexa-His tagged target enzyme, 5% DMSO, 
150 M Cro-CoA, and 150 M NADH in an overall volume of 100 L in the following 
various assay buffers: CdFabK Salt Assay Buffer 1 (HEPES pH 7.5, 0 mM NH4Cl, and 
4% glycerol), CdFabK Salt Assay Buffer 2 (HEPES pH 7.5, 100 mM NH4Cl, and 4% 
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glycerol), CdFabK Salt Assay Buffer 3 (HEPES pH 7.5, 300 mM NH4Cl, and 4% 
glycerol), and CdFabK Salt Assay Buffer 4 (HEPES pH 7.5, 500 mM NH4Cl, and 4% 
glycerol). DMSO and enzyme were incubated together for 5 minutes before the Cro-CoA 
substrate was added and the reaction was started immediately afterward via the addition 
of NADH. NADH absorbance (340 nm) was measured in a Biotek Synergy H1 
microplate reader (Winooski, VT) in a final volume of 100 L in Greiner Bio-One™ 
384-Well µClear™ Bottom Polystyrene Microplates (Monroe, NC) via 20 second 




Trials were conducted in the presence of 50 nM CdFabK_15b N-term hexa-His 
tagged target enzyme, 5% DMSO, 150 M Cro-CoA, and 150 M NADH in an overall 
volume of 100 L in the following various assay buffers: CdFabK Glycerol Assay Buffer 
1 (HEPES pH 7.5, 500 mM NH4Cl, and 0% glycerol), CdFabK Glycerol Assay Buffer 2 
(HEPES pH 7.5, 500 mM NH4Cl, and 4% glycerol), CdFabK Glycerol Assay Buffer 3 
(HEPES pH 7.5, 500 mM NH4Cl, and 10% glycerol), and CdFabK Glycerol Assay 
Buffer 4 (HEPES pH 7.5, 500 mM NH4Cl, and 15% glycerol). DMSO and enzyme were 
incubated together for 5 minutes before the Cro-CoA substrate was added and the 
reaction was started immediately afterward via the addition of NADH. NADH 
absorbance (340 nm) was measured in a Biotek Synergy H1 microplate reader 
(Winooski, VT) in a final volume of 100 L in Greiner Bio-One™ 384-Well µClear™ 
Bottom Polystyrene Microplates (Monroe, NC) via 20 second intervals for 7 minutes to 
evaluate the rate of reaction. 
 
Buffer and pH trials 
 
Trials were conducted in the presence of 50 nM CdFabK_15b N-term hexa-His 
tagged target enzyme, 5% DMSO, 150 M Cro-CoA, and 150 M NADH in an overall 
volume of 100 L in the following various assay buffers: CdFabK pH Assay Buffer 1 
(100 mM MES pH 5.5, 500 mM NH4Cl, and 10% glycerol), CdFabK pH Assay Buffer 2 
(100 mM MES pH 6.5, 500 mM NH4Cl, and 10% glycerol), CdFabK pH Assay Buffer 3 
(100 mM HEPES pH 7.5, 500 mM NH4Cl, and 10% glycerol), CdFabK pH Assay Buffer 
4 (100 mM HEPES pH 8.5, 500 mM NH4Cl, and 10% glycerol), and CdFabK pH Assay 
Buffer 5 (100 mM CHES pH 9.5, 500 mM NH4Cl, and 10% glycerol). DMSO and 
enzyme were incubated together for 5 minutes before the Cro-CoA substrate was added 
and the reaction was started immediately afterward via the addition of NADH. NADH 
absorbance (340 nm) was measured in a Biotek Synergy H1 microplate reader 
(Winooski, VT) in a final volume of 100 L in Greiner Bio-One™ 384-Well µClear™ 
Bottom Polystyrene Microplates (Monroe, NC) via 20 second intervals for 7 minutes to 






CdFabK Stability Trials 
 
Initial  -Globulins dilution assays 
 
Stability assays were carried out at 25°C in the presence of 50 nM CdFabK_15b 
N-term hexa-His tagged target enzyme, 10% DMSO, 150 M Cro-CoA, and 150 M 
NADH in an overall volume of 100 L, in CdFabK Assay Buffer (HEPES pH 8.0, 500 
mM NH4Cl, and 10% glycerol). The enzyme was diluted from the 100 M storage stock 
concentration to 1 M working stock concentration in CdFabK Assay Buffer with 
varying amounts of -Globulins (Sigma Aldrich, St. Louis, MO)—ranging from 0 mg/mL 
(0 mg/mL overall assay concentration) to 2.5 mg/mL (0.125 mg/mL overall assay 
concentration), and then allowed to incubate at 25°C for 0, 30, and 60 minutes. Enzyme 
from each time point and -Globulin dilution concentration was then incubated with 
DMSO as a positive control for 10 minutes before the Cro-CoA substrate was added and 
the reaction was started immediately afterward via the addition of 50 L 300 M NADH. 
NADH fluorescence (340 nm/460 nm) was measured in a Biotek Synergy H1 microplate 
reader (Winooski, VT) in a final volume of 100 L in Greiner Bio-One™ 384-Well 
µClear™ Bottom Polystyrene Microplates (Monroe, NC) via 20 second intervals for 10 
minutes to evaluate the rate of reaction. 
 
 Optimizing -Globulins dilution assays 
 
Maximal CdFabK dilution assays were carried out at 25°C in the presence of two-
fold dilutions of 50 nM CdFabK_15b N-term hexa-His tagged target enzyme down to 
6.25 nM CdFabK_15b. Assays were carried out in 10% DMSO, 300 M Cro-CoA, and 
125 M NADH in an overall volume of 100 L, in CdFabK Assay Buffer (HEPES pH 
8.0, 500 mM NH4Cl, and 10% glycerol). The enzyme was diluted from the 100 M 
storage stock concentration to 1 M, 0.5 M, 0.25 M, and 0.125 M working stock 
concentrations in CdFabK Assay Buffer with an increased 5 mg/mL  -Globulins (0.25 
mg/mL overall assay concentration), and then allowed to incubate at 25°C for 30 
minutes. Enzyme was then incubated in assay buffer with DMSO as a positive control for 
10 minutes before the Cro-CoA substrate was added and the reaction was started 
immediately afterward via the addition of 50 L 250 M NADH. NADH fluorescence 
(340 nm/460 nm) was measured in a Biotek Synergy H1 microplate reader (Winooski, 
VT) in a final volume of 100 L in Greiner Bio-One™ 384-Well µClear™ Bottom 
Polystyrene Microplates (Monroe, NC) via 15 second intervals for 30 minutes to evaluate 







C-term hexa-histidine tagged CdFabK_21d was crystallized at 5 mg mL-1 in a 
3uL:3uL 1:1 ratio protein to condition using the hanging-drop vapor-diffusion method off 
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of a coarse-matrix screen. The initial crystal growth condition was Morpheus (Molecular 
Dimensions, Maumee, OH) condition 1-48 (0.12 M alcohols mix of 0.2 M 1,6-
hexanediol, 0.2 M 1-butanediol, 0.2 M 1,2-propanediol, 0.2 M 2-propanol, 0.2 M 1,4-
butanediol, and 0.2 M 1,3-propanediol; 0.1 M buffer mix of Tris base and BICINE, pH 
8.5; and 37.5% v/v precipitant mix of 25% v/v 2-methyl-2,4-pentanediol, 25% 
polyethylene glycol 1000, and 25% polyethylene glycol 3500) at 18°C. Crystals were 
collected for X-ray diffraction analysis. Crystals were grown in 48-well VDX plates with 




N-term hexa-histidine tagged CdFabK_15b was crystallized at 4.8 mg mL-1 in a 
7uL:7uL 1:1 ratio protein to condition using the hanging-drop vapor-diffusion method off 
of a coarse-matrix screen. The initial crystal growth condition was Morpheus (Molecular 
Dimensions, Maumee, OH) condition 2-48 (0.1 M amino acids mix of 0.2 M DL-
glutamic acid monohydrate, 0.2 M DL-alanine, 0.2 M glycine, 0.2 M DL-lysine 
monohydrochloride, and 0.2 M DL-serine; 0.1 M buffer mix of Tris base and BICINE, 
pH 8.5; and 37.5% v/v precipitant mix of 25% v/v 2-methyl-2,4-pentanediol, 25% 
polyethylene glycol 1000, and 25% polyethylene glycol 3500) at 18°C. Crystals were 
collected for X-ray diffraction analysis. Optimized crystals were then obtained via co-
crystallization in the same Morpheus 2-48 condition at 4.8 mg ml -1 in 7uL:7uL 1:1 ratio 
of protein to a mix of 93% crystallization condition and 7% 10 mM phenylimidazole 
compound 1g (see Chapter 4) in DMSO. Crystals were obtained using the hanging-drop 
vapor-diffusion method. Crystals were grown in 48-well VDX plates with sealant 






Cloning and Expression of Recombinant CdFabK 
 
Substantial amounts of pure, active target CdFabK protein are needed for the 
various characterization and validation studies required for effective CdFabK-directed 
drug discovery and development efforts. Again, cloning into various histidine affinity tag 
systems was chosen and implemented. For the sake of speed, the C. difficile fabK gene 
was commercially optimized, cloned, and inserted into the pET15b vector 
(CdFabK_15b), introducing the popular hexa-Histidine (hexa-His) tag at the N-terminus 
of the target enzyme for effective first-round purification.123 For thorough analysis, the 
target gene was previously cloned into several alternative vectors to study the effects of 
affinity tag placement at either the amino or carboxy terminus, as well as native enzyme 
without any tag. BL21(DE3)-Gold Competent cells were used for the over-expression of 






Purification of Recombinant CdFabK Constructs 
 
As a traditional first step purification method for many target enzymes, Ni2+-NTA 
IMAC purification of CdFabK with the pET21d C-term hexa-His tag system and the 
pET15b N-term hexa-His tag system both resulted in high yields (greater than 25 mg/L) 
of initially active enzyme when high levels of glycerol, such as 18%, were used 
throughout the purification steps. As the C-term hexa-His tagged enzyme (CdFabK_21d) 
proved to lose activity rapidly, the N-term hexa-His tagged construct (CdFabK_15b) 
became the construct of choice. Following successful IMAC purification, further 
purification of CdFabK_15b was carried out via size exclusion chromatography and 
resulted in highly pure enzyme of at least 95% purity via SDS-PAGE analysis (Figure  
3-1) and high overall yields greater than 10 mg/L determined via 660nm protein 
concentration assay with BSA as a standard. Target enzyme solubility was determined 
satisfactory for immediate pooling and purifying via SEC without needing to buffer 
exchange or dialyze, leading to a highly rapid and simple purification protocol that can be 
conducted in one to two days. Under current storage conditions at -80°C (Materials and 
Methods), enzyme has been determined active for over six months. 
 
The native CdFabK target enzyme was also purified via preliminary anion 
exchange chromatography, but the purity in comparison to the N-term hexa-His tagged 
construct was quite poor and further protocol development for purifying the native target 
enzyme was suspended for the time being.  
 
 
Characterization of CdFabK 
 
As the overall stability of CdFabK_21d had been determined previously to be 
very poor, CdFabK_15b was expressed, purified, and tested for comparative stability. Via 
systematic stability and activity trials, effective assay conditions were determined for 
CdFabK_15b with a trend of relatively high NH4Cl, relatively high glycerol, and slightly 
basic pH conditions combining for optimal conditions of HEPES pH 8.0, 500 mM 
NH4Cl, and 10% glycerol (Figure 3-2). Even with the optimized assay conditions, 
however, the target enzyme lost activity soon after being diluted to concentrations needed 
for making a working enzyme stock solution for compound screening. The addition of 
just 2.5 mg/mL -Globulins to the dilution buffer was determined to greatly increase the 
duration of activity of the diluted enzyme at an overall concentration of 50 nM from just 
a few minutes up to at least one hour (Figure 3-3). Additionally, increasing the -
Globulins even further to 5 mg/mL and doubling the substrate concentration to account 
for extended assay duration to 300 M allowed for further dilutions of enzyme 
concentration down to single-digit nanomolar (6.25 nM) with the capability of sustained 







Figure 3-1. SDS-PAGE gel of CdFabK_15b purification results.  
 
(A) Stain-free SDS-PAGE. L, ladder; CE, clarified extract from IPTG-induction growth; 
Ni2+, target fraction from nickel column; SE1, target fraction from beginning of size 







Figure 3-2. Enzyme activity studies of CdFabK_15b.  
 
(A) CdFabK_15b stability trials measuring enzyme activity in different NH4Cl salt 
concentrations, 0 mM (blue line with squares), 100 mM (green line with dots), 300 mM 
(purple line with diamonds), and 500 mM (red line with squares). (B) CdFabK_15b 
stability trials measuring enzyme activity in different glycerol concentrations, 0% (black 
line with triangles), 4% (orange line with diamonds), 10% (red line with squares), and 
15% (blue line with dots). (C) CdFabK_15b stability trials measuring enzyme activity in 
different buffers and at different pH values, MES pH 5.5 (blue line with dots), MES pH 
6.5 (red line with squares), HEPES pH 7.5 (green line with triangles), HEPES pH 8.0 
(black line with dots), HEPES pH 8.5 (orange line with diamonds), and CHES pH 9.5 
(purple line with upside down triangles). All reactions were carried out in the presence of 






Figure 3-3. Enzyme dilution and stability studies of CdFabK_15b.  
 
(A) CdFabK_15b stability trials measuring enzyme activity while diluted to 50 nM at 
different incubation times 0 minutes (green line with circles), 30 minutes (red line with 
squares), and 60 minutes (blue line with triangles). (B) CdFabK_15b stability trials 
measuring enzyme activity while diluted to 50 nM at different incubation times 0 minutes 
(green line with circles), 30 minutes (red line with squares), and 60 minutes (blue line 
with triangles) after having been diluted into a working stock including 2.5 mg/mL of -
Globulins and an overall assay concentration of 0.125 mg/mL -Globulins. All reactions 
were carried out in the presence of a fixed concentration of NADH (150 M) and Cro-










Figure 3-4. Extended enzyme dilution and stability studies of CdFabK_15b.  
 
CdFabK_15b stability trials measuring enzyme activity at different two fold dilutions 50 
nM (blue line with dots), 25 nM (red line with squares), 12.5 nM (green line with 
triangles), and 6.25 nM (purple line with upside down triangles), and NADH control 
without enzyme (orange line with diamonds) after thirty minutes of incubation and a 
reaction runtime of thirty minutes. CdFabK_15b was diluted into a working stock 
including 5 mg/mL of -Globulins and an overall assay concentration of 0.25 mg/mL -
Globulins. All reactions were carried out in the presence of a fixed concentration of 






Crystallization of CdFabK_21d and CdFabK_15b 
 
Crystallization conditions were determined for both CdFabK_21d and 
CdFabK_15b (Figure 3-5). Protein crystals of CdFabK_21d were discovered first and 
diffracted to roughly 4 Å. CdFabK_15b crystallization conditions were also determined, 
and moderately optimized (as discussed in Materials and Methods) with the resulting 








 CdFabK was produced with two different hexa-Histidine tags, each to high 
homogeneity and purity (greater than 95% via SDS-PAGE analysis) and over 10 mg per 
liter of culture, however the C-term His-tagged construct proved highly unstable, despite 
significant efforts to optimize storage and activity assay conditions (data now shown). 
Therefore, the N-term His-tagged construct was expressed, purified via two-step 
purification, and studied further. Upon systematic stability and activity trial analysis, the 
salt, glycerol, and buffer and pH conditions were optimized for this specific construct as 
discussed below. While stored at -80°C, the activity of the enzyme remains well past six 
months, which is an important factor considering the desire to make large amounts of a 
single batch of enzyme, store it, and use it in the future for reliable and uniform and 





Upon systematic optimization of activity buffer conditions, optimal conditions 
were found to be 100 mM HEPES pH 8.0, 500 mM NH4Cl, and 10% glycerol. This takes 
into account many considerations as the eventual goal of CdFabK production includes 
future assay development for compound screening and inhibitor studies. As such, certain 
factors of concern include, of course, target enzyme stability and activity during both 
benchtop experiments as well as after long-term storage.180 During analysis of the activity 
of the CdFabK_15b enzyme under diluted conditions generally conducive to creating 
working enzyme stock concentrations needed for compound screening, it was discovered 
that any significant dilution of CdFabK_15b below ~100 M resulted in relatively rapid 
inactivation. Thus the addition of inert proteins were analyzed and the addition of -
Globulins to the assay buffer for the dilution of the enzyme storage stock to an enzyme 
working stock was determined to greatly increase the overall stability of the enzyme with 
respect to the duration of activity. This allowed for substantial dilutions that would afford 
the opportunity to conduct assays in the presence of reasonable concentrations of DMSO 







Figure 3-5. CdFabK crystals. 
 
A. Original CdFabK_21d C-term hexa-His tagged crystals grown at 18°C from coarse 
Morpheus screen, condition 1-48 (0.12 M alcohols mix of 0.2 M 1,6-hexanediol, 0.2 M 1-
butanediol, 0.2 M 1,2-propanediol, 0.2 M 2-propanol, 0.2 M 1,4-butanediol, and 0.2 M 
1,3-propanediol; 0.1 M buffer mix of Tris base and BICINE, pH 8.5; and 37.5% v/v 
precipitant mix of 25% v/v 2-methyl-2,4-pentanediol, 25% polyethylene glycol 1000, and 
25% polyethylene glycol 3500). B. Optimized CdFabK_15b crystal grown at 18°C from 
coarse Morpheus screen, condition 2-48 (0.1 M amino acids mix of 0.2 M DL-glutamic 
acid monohydrate, 0.2 M DL-alanine, 0.2 M glycine, 0.2 M DL-lysine 
monohydrochloride, and 0.2 M DL-serine; 0.1 M buffer mix of Tris base and BICINE, 
pH 8.5; and 37.5% v/v precipitant mix of 25% v/v 2-methyl-2,4-pentanediol, 25% 
polyethylene glycol 1000, and 25% polyethylene glycol 3500) with 1:1 protein to 7% 10 
mM phenylimidazole compound 1g (see Chapter 4) and DMSO in Morpheus 








CdFabK required certain conditions for activity and stability, namely high salt, at 
least 300 mM NH4Cl, and high glycerol, 18%, not traditionally conducive to 
crystallization. As different methods were being considered for the optimization of 
crystallization standards, coarse crystallization trials were nonetheless attempted in the 
meantime. To some degree of surprise, crystallization conditions for both the C-term and 
N-term His-tagged constructs were discovered, despite the high salt and high glycerol 
storage buffer conditions. While certainly a noteworthy accomplishment, the crystals 
continually resulted in lower, relatively weak diffraction (higher than 3.5 Å) and were 
therefore of little use in structure-guided drug development efforts.  
 
Fine screening crystallization attempts were made to the best of in-lab abilities, 
but initial efforts to do so were met with difficulty. The crystallization conditions were 
very complex, including combinations of multiple precipitants like MPD, PEG 1000, and 
PEG 3350 for both CdFabK construct hit conditions, and different complex ligand 
combinations that include a mix of six different alcohols for the initial C-term hit 
condition, and a complex ligand mix of five different amino acids for the N-term hit 
condition. Therefore, the realistic opportunity for fine screening was somewhat limited 
from the beginning and did not yield further results. As the crystals found off of the 
coarse screens were not shown to diffract near 2 Å, three-dimensional crystal structures 
have not been determined. Instead, additional crystallization and crystal optimization 
trials have continued.  
 
Such trials have included apo- and co-crystallography efforts with CdFabK_15b 
and analogues of a known phenylimidazole FabK inhibitor compound.163 Additionally, 
CdFabK_15b has been screened against multiple other coarse crystal screens at various 
temperatures. Also, protein to crystallization condition ratios have been altered, as have 
drop sizes, and hanging vs. sitting drop methods have been employed. An Additive 
Screen (Hampton Research, Aliso Viejo, CA) has also been attempted, and different cryo 
conditions have been analyzed, including various PEG compounds, glycerol contents, 
sugars, oils, and so on. Various post-crystallization techniques reported in the literature, 
such as annealing and denaturing methods, have been extensively attempted as well.181 
Thus far, diffraction has not improved, and further consideration is undergoing. 
 
Though generally reported in the literature to have little effect on crystal structure 
quality and resolution, another consideration has been that the His-tag may interfere with 
tight crystal packing and resulting resolution.182 As such, attempts were made to cleave 
the His-tag off of CdFabK_15b via thrombin cleavage, but enzyme activity was 
completely lost and not recovered after doing so (data not shown). It is surmised that the 
reason for this is the extensive degree of dilution for extended amounts of time required 
for the thrombin cleavage reaction to occur. Additionally, preliminary attempts have been 
made to purify native, untagged CdFabK for eventual crystallization trials but, similar to 







Recent studies have shown that the fabk gene in C. difficile, which codes for the 
CdFabK enzyme, is essential, even in the presence of exogenous fatty acids.67 This alone 
supports CdFabK as a potentially promising novel antibacterial target. However, as those 
studies also show that a known inhibitor of CdFabK inhibits the growth of C. difficile 
without substantially inhibiting the growth of several selected representatives of the 
human microbiome, the promise and potential of CdFabK as a narrow-spectrum 
antibacterial target is also notably suggested.67 In order to further investigate CdFabK as 
a narrow spectrum target for antibacterial drug discovery, it was immediately necessary 
to produce pure, active, and stable target protein for further characterization and 
validation.  
 
CdFabK initially proved to be a relatively unstable enzyme in that traditional 
purification buffers resulted in low-yield and inactive target protein. Via iterative trials, 
substantial yields of highly pure and active CdFabK are now rapidly obtainable. 
Moreover, conditions for reproducible and reliable assaying of the target enzyme have 
been determined, including assay buffer conditions and long-term storage conditions. 
While the activity of the enzyme can now be reliably measured at a satisfactory 50 nM 
conentration, the potential for measuring even lower concentrations—potentially into low 
double-digit nanomolar to single-digit nanomolar concentrations—appears possible. As 
this would be necessary for the testing of any potent CdFabK inhibitors discovered or 
developed, this is indeed a substantial and necessary achievement. Immediate future 
research, therefore, should include compound screening against CdFabK, as well as 
enzymology and characterization of known FabK inhibitors (discussed further in Chapter 
4). 
 
Aside from producing pure, stable, and active enzyme for future compound 
screening, solving the three-dimensional CdFabK structure via X-ray crystallography is 
extremely important for future structure-guided drug discovery efforts. Unfortunately, the 
crystallography results reported herein did not include crystallization conditions or 
crystals that yielded the resolution needed to determine the structure of CdFabK at atomic 
or near-atomic resolution (near 2 Å or lower), which would be necessary to observe 
structural characteristics in high detail and molecular interactions for potential ligands. 
Accordingly, future research should include continued crystallography efforts, both 
aimed at further optimizing diffraction of current crystals from known crystallization 
conditions, as well as determining new crystallization conditions and potentially 
constructing FabK mutants for additional crystallography studies (discussed further in 












FabK from S. pneumoniae (SpFabK) was shown by Takahata et al. to be 
specifically inhibited by a compound (AG-205) they found during a high throughput 
screening campaign, which led to the development of the more potent phenylimidazole-
derived class of inhibitors via iterative medicinal chemistry modifications (e.g., replacing 
the amide linker with urea functionality, exploring various substitutions at the solvent 
exposed head region, un-fusing the benzimidazole and benzothiazole ring systems, and 
evaluating various substitutions at the tail region).166,168,183-185 Despite substantial gains in 
potency, further development was ceased, possibly due to the unfortunate fact that 
Streptococci are able to bypass FAS-II inhibition as they carry the FabT regulatory 
system.171 Because C. difficile harbors the FapR regulatory system, it presents an 
opportunity to renew the development of phenylimidazole FabK inhibitors.186 In an effort 
to characterize the enzyme target, essential kinetic evaluations of CdFabK, including 
substrate and cofactor Km determinations, inhibition modality, and substrate inhibition 
effects are herein performed. Data is also reported showing phenylimidazoles display 
potent on-target biochemical activity against CdFabK (Table 4-1) and are amenable to 
modifications that improve physiochemical properties (Figure 4-1) while maintaining 
biochemical and anti-C. difficile activity.  
 
As discussed above, the type II bacterial fatty acid synthesis pathway, FAS II, 
provides important fatty acid precursors for membrane phospholipids essential to 
bacterial cells and integral to sporulation. The FAS II pathway is distinctly separate from 
the mammalian FAS I pathway, which is composed of a single, multifunctional synthase, 
thus the FAS II enzymes represent novel and selective antibacterial targets that remain 
relatively unexploited.  The structure and function of the enzymes in the bacterial FAS II 
pathway have been previously reviewed.169,187-189  As a metabolic pathway there is some 
concern about the ability of bacteria to bypass FAS II inhibition using exogenous fatty 
acids and this has been the subject of intense debate.171-173  
  
Recent work, however, has demonstrated that certain bacteria, including S. 
aureus, remain susceptible to FAS II inhibition even in the presence of exogenous fatty 
acids due to differences in their regulation of genetic expression and feedback regulatory 
systems.71,190  As a rate-limiting enzyme in the FAS-II pathway, FabI, enoyl-[acyl-carrier 
protein (ACP)] reductase, represents a particularly attractive drug target and a number of 
inhibitors of this enzyme have been characterized.30,31,177,191-199  Triclosan, a stereotypical 
FabI inhibitor with a diphenyl ether scaffold, has been marketed for a number of years  
 
                                                 
 
4 Portions of chapter from final submission adapted with permission from Jones, J. A.* et al. Small-
molecule inhibition of the C. difficile FAS-II enzyme, FabK, results in selective activity. ACS Chem Biol, 
https://doi.org/10.1021/acschembio.9b00293 (2019. In Press). (*Co-first author.) Copyright (2019) 




Table 4-1. Inhibitory activity of Enoyl-ACP isozymes by phenylimidazole 
analogues. 
 
Compound CdFabK IC50 [95% CI]; 
% Inhibition at 10 M  
SpFabK IC50 [95% CI] 
Triclosan >100 M >100 M 
1a >10 M; 38.51% 0.730 M [0.434, 1.456] 
1b 3.31 M; 95% CI [2.68, 4.19] 0.067 M [0.054, 0.084] 
1c >10 M; 49.86% 0.242 M [0.214, 0.274] 
1d >10 M; 44.80% 0.198 M [0.178, 0.222] 
1e 2.86 M [2.02, 4.35] 0.078 M [0.066, 0.093] 
1f 4.63 M [3.12, 8.02] 0.163 M [0.124, 0.214] 
1g 7.35 M [5.35, 11.65] 0.085 M [0.072, 0.101] 
1h >10 µM; 35.58% 0.538 M [0.433, 0.675] 
AG-205 4.15 M [3.324, 5.597] 5.32 M [4.378, 6.809] 
 
CI, Confidence Interval 
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and is used in a variety of over-the-counter household products as a sterilizing agent, 





While the fabk gene has been well-validated as an essential gene in C. difficile 
within the literature, the necessity to further validate the CdFabK enzyme as a druggable, 
selective antibacterial target still exists.67 In an effort to do so, the following work details 
essential kinetic evaluations of CdFabK, including substrate and cofactor Km 
determinations; substrate inhibition effects; and inhibition studies, including modality 
data of phenylimidazole compounds and preliminary inhibition data of novel 
benzothiazole compounds against CdFabK. 
 
 
Materials and Methods 
 
 
CdFabK_15b Cloning, Expression, Purification 
 
 The N-term hexa-histidine tagged CdFabK enzyme, CdFabK_15b, was produced 
and purified as detailed previously in Chapter 3 and used for all CdFabK enzymology, 
kinetic, and inhibitor studies discussed in this chapter. 
 
 
SpFabK Cloning and Plasmid Construction 
 
The fabk gene from S. pneumo strain R6 was cloned and amplified using standard 
PCR protocol and restriction enzyme techniques. Primers were designed around the NdeI 
and BamHI restriction sites using the following primers: 
 
SpFabKfwd: 5’-GGAGGCATATGAAAACGCGTATTAC-3’  
 
SpFabKrev: 5’-AAGGATCCTTAGTCATTTCTTACAACTCC -3’ 
 
The target gene was cloned into the pET15b vector and transformed into BL21-Gold 
(DE3) cells (Agilent Technologies, Santa Clara, CA). The protein was overexpressed in 
E. coli BL21-Gold (DE3) cells via cultivation at 37°C in TB medium with 100 g/mL 
ampicillin by first transferring 1% (v/v) overnight culture into fresh medium. Cells were 
allowed to grow until OD600 of ~ 0.6 and the protein expression was induced with 0.1 
mM IPTG. Cells were allowed to grow further for 18 hours at 18C and the cells were 
harvested by centrifugation at 18000 x g for 15 minutes. After induction and growth, the 
cells were harvested by centrifugation at 18000 x g for 15 minutes. Pellets were stored at 







The cell pellet was resuspended in 50 mL SpFabK Lysis Buffer (CdFabK Buffer 
A with 0.5 mg/mL lysozyme, 1mg/100mL DNase, 5 mM MgCl2, 0.5% Triton-X, and 1 
Pierce EDTA-free Protease Inhibitor tablet per 50 mL) and lysed at 4°C with gentle 
stirring, then sonicated on ice at 50% amplitude for eight minutes, with eight seconds on 
and 24 seconds off.  The cell lysates were centrifuged at 39000 x g for 15 min and the 
supernatant was passed through a 0.22 µM PES syringe filter (EMD Millipore, Billerica, 
MA). N-term hexa-histidine tagged SpFabK (SpFabK_15b) was purified via immobilized 
metal affinity chromatography (IMAC) by loading the filtered lysate on a HisTrap HP 
column (GE Life Sciences) in SpFabK Buffer A, washed over 20 column volumes with 
SpFabK Buffer A, and eluted via linear gradient to 100% SpFabK Buffer B (SpFabK 
Buffer A with 500 mM imidazole) over 20 column volumes. After IMAC purification, 
fractions were pooled and further purified by size exclusion chromatography (SEC) on a 
HiLoad 26/600 Superdex 200 PG size exclusion column (GE Healthcare Life Sciences, 
Pittsburgh, PA) in SpFabK SEC Buffer (50 mM Tris pH 7.4, 100 mM NH4Cl, and 3 mM 
DTT) via isocratic elution. The enzyme was confirmed via PAGE gel analysis and the 
enzyme activity was analyzed in an Implen NP80 nanophotometer as described below 
(West Lake Village, CA). The protein was concentrated to 75 µM with 35% overall 





FabI from S. aureus cloned into the pET15b vector (SaFabI_15b) was 
transformed into BL21-Gold (DE3) cells (Agilent Technologies, Santa Clara, CA) 
previously (data not shown), and SaFabI_15b was produced in high yield and purity as 
reported elsewhere in the literature with minor modifications.194 Briefly, SaFabI_15b was 
overexpressed at 37°C in TB medium with 100 g/mL ampicillin by transferring 1% 
(v/v) overnight culture into fresh medium. Cells were allowed to grow until they reached 
an OD600 of ~ 0.6 and the protein expression was induced with 0.5 mM IPTG grown 
further for 4 hours at 37°C. After induction and growth, the cells were harvested by 





The cell pellet was resuspended in 50 mL SaFabI Buffer A (500 mM Tris pH 8.0, 
500 mM NaCl, and 10 mM imidazole) with 0.5 mg/mL lysozyme, 1mg/100mL DNase, 5 
mM MgCl2, 0.5% Triton-X, and 1 Pierce EDTA-free Protease Inhibitor tablet per 50 mL, 
and lysed at 4°C with gentle stirring, then sonicated on ice at 50% amplitude for eight 
minutes, with eight seconds on and 24 seconds off. The cell lysate was centrifuged at 
39000 x g for 15 minutes and the supernatant was passed through a 0.22 µM PES filter 
(EMD Millipore, Billerica, MA). The target protein purification was performed by 
affinity chromatography on HisTrap HP column (GE Lifesciences) with SaFabI Buffer A 
as binding and wash buffer and SaFabI Buffer B (SaFabI Buffer A with 500 mM 
 
85 
imidazole) as elution buffer. Elution peaks were pooled and buffer exchanged in a 10,000 
MWCO  AmiconTM Ultra-15 Centrifugal Filter Unit from EMD Millipore® (Billerica, 
MA) into SaFabI Storage Buffer (50 mM MES pH 5.5, 100 mM NaCl, 100 mM EDTA). 
 
SaFabI_15b was confirmed via PAGE gel analysis and the enzyme activity was  




FAS-II Biochemical Enzyme Assays 
 
All compounds were dissolved in DMSO at concentrations of 10 mM, then 
further diluted in pure DMSO to the required concentrations.  Both CdFabK and SpFabK 
assays were conducted via the following protocol: Reactions were carried out at 25C in 
FabK Assay Buffer (100 mM HEPES pH 8.0, 500 mM NH4Cl, 10% glycerol, and 0.125 
mg/mL -Globulins; 10% DMSO) with 150 M Cro-CoA and 150 M NADH. 
Compounds were incubated in three-fold dilutions (ranging from 100 M to 5 nM for 
CdFabK and 33 M to 1.7 nM for SpFabK) in the presence of 50 nM target enzyme. 
Compounds and enzyme were incubated together for 10 minutes before the Cro-CoA 
substrate was added and the reaction was started immediately afterward via the addition 
of NADH. NADH fluorescence (340 nm/460 nm) was measured in a Biotek Synergy H1 
microplate reader (Winooski, VT) in a final volume of 100 L in Greiner Bio-One™ 
384-Well µClear™ Bottom Polystyrene Microplates (Monroe, NC) via 20 second 
intervals for 10 minutes to evaluate the rate of reaction.  
 
SaFabI assays were conducted at 25 C in FabI Assay Buffer (50 mM MES pH 
5.5, 150 mM NaCl, 10 mM EDTA, and 2% DMSO) with 300 M NADPH and 1 mM 
Cro-CoA. Compounds were incubated at 10 M with 500 nM SaFabI for 20 minutes. 
Reactions were started via the addition of NADPH. NADPH absorbance was measured 
(340 nm) every 10 seconds for 10 minutes in a final volume of 100 L to evaluate the 
rate of reaction.  
 
 
FabK IC50 Calculations and Kinetics  
 
Starting at three minutes, linear slopes were measured for three additional minutes 
and used to determine the reaction rates. Measurements were conducted in duplicate and 
IC50s were calculated via GraphPad Prism 7.0d (La Jolla, CA) using four-parameter 
logistic (Hill) curve analysis using the equation Y = Bottom + (Top – 
Bottom)/[1+10^((LogIC50 – X)*HillSlope)], where X is logarithm of dose and Y is 
response. Kinetics with respect to cofactor and substrates were also assessed via 






FabI Activity  
 
Starting at two minutes, linear slopes were measured for three minutes and used to 
determine the reaction rates. Measurements were conducted in duplicate and percent 
inhibitions were calculated against un-inhibited enzyme.  
 
 
Generation of SpFabK and CdFabK Sequence Alignment 
 
SpFabK and CdFabK alignment figure generated with ESPript 3 server 
(http://espript.ibcp.fr) using multiple protein sequence alignment from Clustal Omega 






The CdFabK Enzyme Possesses Intrinsic NADH Oxidative Activity and Double 
Substrate Inhibition 
  
The CdFabK enzyme displayed NADH oxidative activity in the absence of enoyl 
substrate (Figure 4-2). Apparent Km (Km
app) values were determined via 1.5-fold serial 
dilutions of the NADH cofactor while holding the enoyl substrate, crotonyl coenzyme A 
(Cro-CoA), constant at 150 M; likewise, 1.5-fold serial dilutions of Cro-CoA were 
tested while holding the NADH cofactor constant at 150 M; and an alternative enoyl 
substrate, octenoyl coenzyme A (Oct-CoA), was tested similarly via 1.5-fold dilutions 
while holding NADH constant at 150 M. Initially, Km
app values were determined via 
standard Michaelis-Menten non-linear regression fits. However, upon further analysis, 
the data for cofactor and substrates all fit a substrate inhibition model (R2 = 0.9854; 
0.7607; and 0.8479, respectively) better than the poorly fit standard Michaelis-Menten 
models. As such, respective Km
app values for NADH, Cro-CoA, and octenoyl coenzyme 
A were determined to be 138.1 M, 327.0 M, and 420.8 M, as opposed to 23.0 M, 




Phenylimidazole-Derived Compounds Selectively Inhibit the C. difficile FabK 
Enzyme  
 
Phenylimidazole compounds have been shown to inhibit SpFabK (PDB 2Z6J) and 
lack inhibitory activity against FabI from E. coli.183,184 To evaluate activity against 
CdFabK, phenylimidazole compounds were screened against purified enzyme to 
determine percent inhibition at 10 M. Compounds yielding over 50% inhibition were 
further screened to determine on-target 50% inhibitory concentrations (IC50). Compounds 
were also screened at 10 M against purified FabI from Staphylococcus aureus (SaFabI) 





Figure 4-2. Enzyme kinetics of CdFabK vs. velocity.  
 
(A) Non-linear regression curve fit of velocity of CdFabK with varying concentrations of 
NADH (1.5-fold dilutions from 350 M to 9.1 M) at a fixed concentration of Cro-CoA 
(325 M) demonstrating NADH substrate inhibition. Standard Michaelis-Menten fit 
(dashed blue line) and substrate inhibition line (solid black line with dots) shown for 
comparison. (B) Non-linear regression curve fit of velocity of CdFabK with varying 
concentrations of enoyl substrate Cro-CoA (1.5-fold dilutions from 4500 M to 78 M 
and 0 M) at a fixed concentration of NADH (125 M) demonstrating Cro-CoA 
substrate inhibition. (C) Non-linear regression curve fit of velocity of CdFabK with 
varying concentrations of alternative enoyl substrate octenoyl-CoA (1.5-fold dilutions 
from 2500 M to 43 M and 0 M) at a fixed concentration of NADH (125 M) 
demonstrating octenoyl-CoA substrate inhibition.  
Reprinted from final submission with permission from Jones, J. A.* et al. Small-molecule 
inhibition of the C. difficile FAS-II enzyme, FabK, results in selective activity. ACS 
Chem Biol, https://doi.org/10.1021/acschembio.9b00293. (2019. In Press). (*Co-first 





We confirmed the phenylimidazole compounds inhibit CdFabK in a dose-
dependent manner. All compounds except 1a, 1c, 1d, and 1h showed greater than 50% 
inhibition of CdFabK at 10 M. IC50s ranged from 7.35 M with 1g to 2.86 M with 1e, 
with the series prototype, 1b, showing an IC50 of 3.31 M. Resulting Hill coefficients 
from IC50 logistic curve fits for 1b, 1e, and 1g were 0.901 (95% Confidence Interval (CI) 
= 0.761-1.064), 0.8594 (95% CI = 0.6449-1.134), and 1.014 (95% CI = 0.7417-1.365), 
respectively. These values are not significantly different from unity (Hill slope of 1.000), 
suggesting these compounds display normal inhibitory behavior and do not bind 
cooperatively, aggregate, form micelles, or demonstrate problematic insolubility. It also 
indicates the enzyme’s active sites function independently, despite CdFabK being a 
functional dimer.163,202 
 
All compounds showed IC50s against SpFabK in the sub-micromolar range, with 
1b resulting in an IC50 of 67 nM, roughly 49-fold better as compared to CdFabK. 
Likewise, 1e and 1g resulted in respective IC50s of 78 and 85 nM against SpFabK, 
illustrating roughly 87- and 37-fold better respective IC50s as compared to CdFabK. 
While activity of 1b against SpFabK was more potent than against CdFabK, it was still 
roughly 30 times less potent against SpFabK in our hands than reported elsewhere.184 As 
the monomer enzyme concentration used here (50 nM) was lower than that used in 
previous reports (about 60 nM), the reason for this discrepancy is not readily apparent. 
FabI was confirmed to be resistant to the phenylimidazole compounds as both 1b and 
AG-205 showed little inhibitory effect against SaFabI with percent inhibition values well 
below 50% (22.40 and 18.22%, respectively) at 10 M. 
 
The target specificity profile of CdFabK was examined via activity in the 
presence of triclosan—a well-known, potent, slow-binding inhibitor of the FabI 
isozyme.203 To verify our own methods, triclosan was confirmed to be a potent inhibitor 
of SaFabI, with nearly 90% inhibition at 10 M. Like SpFabK, CdFabK proved to be 
resistant to triclosan at 100 M and IC50 values were not determined. 
 
 
Phenylimidazole Compound 1b is Competitive for NADH and Uncompetitive for the 
Enoyl Substrate Against CdFabK 
 
To elucidate the modality of inhibition of the phenylimidazole compounds against 
CdFabK, we analyzed the inhibitory activity of 1b against purified enzyme in the 
presence of varying concentrations of NADH while holding Cro-CoA constant, and 
likewise in the presence of varying concentrations of Cro-CoA while holding NADH 
constant. Both non-linear fits and Lineweaver-Burk plots were analyzed. The best non-
linear fits for each substrate suggest that 1b acts as a competitive inhibitor of CdFabK 
with respect to NADH (R2 = 0.91) and an uncompetitive inhibitor with respect to Cro-
CoA (R2 = 0.90). The Lineweaver-Burk plots for each substrate corroborate these 








Figure 4-3. Characterization of inhibitory activity and mechanism of 1b against 
CdFabK. 
 
(A) Sigmoidal plots demonstrating dose response curves for the inhibition of CdFabK by 
two different phenylimidazole analogues, 1b (black line with dots) and 1g (blue line with 
triangles). (B) Sigmoidal plots as dose response curves for the inhibition of CdFabK by 
1b with different concentrations of Cro-CoA, 150 µM Cro-CoA (black line with dots) 
and 325 µM Cro-CoA (red line with squares). (C) Lineweaver-Burk plot showing 
competitive inhibition of CdFabK binding NADH by 1b. CdFabK was incubated with 
varying concentrations of 1b and NADH at a fixed concentration of Cro-CoA (325 µM). 
Concentrations of 1b were 33 µM (closed circle), 11 µM (square), 3.67 µM (triangle), 
1.22 µM (upside-down triangle), 0.4 µM (diamond), and 0 µM (open circle). (D) 
Lineweaver-Burk plot showing uncompetitive inhibition of CdFabK binding Cro-CoA by 
1b. CdFabK was incubated with varying concentrations of 1b and Cro-CoA at a fixed 
concentration of NADH (150 µM). Concentrations of 1b were 33 µM (closed circle), 11 
µM (square), 3.67 µM (triangle), 1.22 µM (upside-down triangle), 0.4 µM (diamond), 
and 0 µM (open circle).  
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Benzothiazole Compound KH-70 Potently Inhibits CdFabK 
 
Benzothiazole compounds have also been shown to inhibit SpFabK.167 
Considering the lack of a significant difference between the observable potencies of 
phenylimidazoles and the prototype benzothiazole compound AG-205 against CdFabK, 
benzothiazole analogues were further considered. A hit determined from a virtual 
screening shape matching campaign conducted by the principal investigator of the 
laboratory resulted in a benzothiazole analogue, KH-70, that was later screened under the 
same optimized Km conditions as 1b (Materials and Methods). KH-70 proved to be the 
most potent inhibitor of CdFabK to date, with an IC50 of 0.3545 M (95% CI 0.2509 to 





We report here the kinetic evaluation of CdFabK, the biochemical activity of a 
series of phenylimidazole analogues, and microbiological data suggesting these 
compounds’ selective antibacterial activity against C. difficile over several other 
prominent gut organisms. The compounds display promising, low micromolar CdFabK 
inhibitory activity without significantly affecting the in vitro growth of important gut 
organisms. CdFabK biochemical activity assays confirmed the inhibitory activity of all 
phenylimidazole analogues against CdFabK, with several showing potent, low 
micromolar activity. This data further demonstrates the enzyme’s druggability and the 
potential of the phenylimidazole compounds as leads for developing a novel series of 
narrow-spectrum anti-C. difficile drug candidates. As the imidazole and thiazole-urea 
moieties in the first-generation inhibitor 1b were predicted in modeling studies to 
establish three hydrogen bond interactions, and thus play a significant role in FabK 
binding, initial structure activity relationship (SAR) and physicochemical exploration 
during druggability validation was focused on the 4-bromo-phenyl region of the molecule 
(Figure 4-1). The calculated solubility of 1b is poor (cLogP 4.56). Therefore, in this 
work, a new expanded set of substituents with different lipophilic and electronic 
properties in the tail region were tested to further probe existing SAR as well as enhance 
solubility. Specifically, six new compounds 1c-1h, along with two known compounds 1a-
b, were evaluated and, while chemical modifications did not substantially increase 
potency, IC50 values against CdFabK indicate inhibitory activity was not abolished 
despite crucial solubility enhancement via modification at this region. This is illustrated 
by comparing 1b (4-bromophenyl, cLogP 4.56 and IC50 3.31 M) and 1g (4-
cyanophenyl, significantly improved cLogP 3.15, similar IC50 7.35 M). Because the 
target enzyme’s natural, in vivo function involves the binding of relatively lipophilic fatty 
acid precursor substrates, this was a noteworthy discovery that will serve as an important 
structural basis for future inhibitor design and synthesis. While 1e and 1f showed MIC 
values similar in potency to 1b and 1g, increased cLogP values (4.6 and 4.8, respectively) 
for both compounds preclude them from further assessment. 
 
A high degree of primary sequence identity and active site similarity exists 





Figure 4-4. Structure and dose response curve against CdFabK for the novel hit 
KH-70. 
 
(A) Structure of benzothiazole hit KH-70. (B) Sigmoidal plot demonstrating dose 






with 2 missing loops on SpFabK, PDB 2Z6J100% and 91% active site identity within 3 Å 
and 4Å from bound inhibitors, respectively; Figure 4-5). Despite this, the 
phenylimidazole compounds showed greater activity against SpFabK than CdFabK (sub-
micromolar vs. low micromolar, respectively). The compounds, along with triclosan, 
were tested against both FabK and FabI to determine comparative FAS-II inhibition 
profiles. The compounds potently inhibited FabK but lacked activity against FabI, while 
triclosan potently inhibited FabI but lacked activity against FabK. The reason for the 
potency disparity of phenylimidazoles against the two similar FabK enzymes is not 
readily apparent. The mode of inhibition for the phenylimidazoles was reported to be 
competitive inhibition of SpFabK binding NADH and uncompetitive of SpFabK binding 
Cro-CoA,163 and confirmed here to be the same against CdFabK (Figure 4-2) and 
therefore not the cause for potency dissimilarity. Evaluation at incorrect Km
app values of 
substrate and cofactor was another potential cause for dissimilar potencies, therefore a 
substrate inhibition model was considered, increasing the Km
app of Cro-CoA to 327 M, 
up from 176 M seen with a standard Michaelis-Menten model. After re-testing 1b 
against CdFabK with 325 M Cro-CoA, the IC50 dropped from 3.31 M to 1.27 M. 
While this resulted in an IC50 closer to that observed against SpFabK, it still represents a 
roughly 19-fold increase and, therefore, also fails to fully explain the discrepancy. A final 
consideration is the possibility that the unique requirement of C. difficile for branched 
chain fatty acids may impact the substrate requirements of CdFabK, making a branched 
enoyl substrate more appropriate than Cro-CoA for compound screening, or even 
introducing the possibility of additional medicinal chemistry modifications to be made to 
the phenylimidazole compounds suited specifically to CdFabK.  
 
Interestingly, a return to the benzothiazole scaffold of AG-205 resulted in the very 
recent discovery of a related compound, KH-70, that has proven to be the most potent 
CdFabK inhibitor to date. In comparison to the phenylimidazole analogues and AG-205, 
KH-70 possesses a shortened linker group and a sulfone moiety, either of which may 
help improve the observed potency (Figure 4-4). Further consideration of benzothiazole 
scaffolds is certainly warranted, and further KH-70 hit characterization and validation are 
ongoing. Without such studies, current rationale for the increased potency of KH-70 
against CdFabK remains, to some extent, speculation. As such, necessary SAR studies 





With the continued use of broad-spectrum antibiotics, the increasingly 
diminishing spectrum of useful anti-CDI antibacterial agents, and the increased incidence 
of new pathogenic strains, the need for novel antibacterial agents targeting C. difficile 
continues to outpace their discovery. As demonstrated in these studies, a notably 
attractive target for antibacterial development resides in the bacterial FAS II pathway, 
which is structurally dissimilar from the mammalian fatty-acid synthesis (FAS I) 
pathway.204 FAS II also contains a number of dissimilar, independent enzymes and 
enzyme homologues collectively responsible for the synthesis of important bacterial fatty 





Figure 4-5. Sequence alignment comparing CdFabK and SpFabK. 
 
Identical residues are highlighted in red, similar residues are highlighted in yellow, and 
active site residues, within 4 Å from phenylimidazole binding site, are indicated with a 
blue dot.119,122  
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Additionally, the pathway has now been well-validated as being essential in both Gram-
negative bacteria and a number of Gram-positive bacteria, even in the presence of 
exogenous fatty acids.  
 
Via direct comparison here of the phenylimidazole compounds’ IC50 values 
against different purified enoyl-ACP reductase enzymes from different organisms, the 
selective druggability of CdFabK can be confirmed. Furthermore, analysis of in vitro 
MIC values of phenylimidazole compounds against various key gut microbes elsewhere 
in the literature has further illustrated this.67 As such, the selective inhibition of CdFabK 
represents a particularly promising pathway for future narrow-spectrum anti-difficile 
development. In vivo efficacy, toxicity, and dysbiosis studies in animal models of 
phenylimidazoles and derivatives will be indispensable for continued development and, 
therefore, are anticipated for future studies. Furthermore, as more information pertaining 
to the human microbiome continues to surface, an ongoing analysis of the distribution of 
current and novel FAS-II isozymes across the increasing number of known gut microbes 
will be of critical importance. Such analyses will guide an evolving understanding of the 











Though the skillset required to address modern rational antibacterial drug 
development may be somewhat daunting at first glance, so is the rising threat of 
antibacterial resistance. It seems only fitting, then, that as the threat of resistance rises, so 
too must an equal measure of intellect and innovation to meet it. As even homologues of 
the same enzyme from different bacterial species may possess vastly different 
characteristics, there is no pre-determined roadmap for addressing the needs one may 
encounter when investigating novel antibacterial targets. Therefore, a wide and thorough 
understanding of the various methods and techniques needed for such endeavors is a 
necessity. Similarly, while even the best equipped laboratories likely do not possess every 
single piece of instrumentation available for drug discovery research, a wide knowledge 
base, experience, and familiarity with various methods and techniques offers the 
adaptability and expertise necessary to overcome even the most difficult projects. Indeed, 
understanding the advantages and disadvantages of different techniques, the overlap, and 
the subtle differences one may offer as opposed to another all combines to benefit the 
researcher.  
 
While certainly not completely exhaustive, an effective combination of methods 
and techniques were used in this work to investigate narrow spectrum antibacterial drug 
targets. As can be observed, all of this work builds upon itself. From rational target 
identification, to target production and preliminary characterization, to compound 
screening and hit selection, to target and hit validation and characterization, and finally to 
lead development and optimization, the techniques employed in this work are 
representative of the necessary methodology required for a rational and early pre-clinical 
investigation of antibacterial drug targets. While the actual near-end stage of discovering 
and developing validated hits is indeed exciting and stands out from the rest of the work, 
it is the early, more tedious research that precedes those discoveries that serves as the 
actual foundation for later breakthroughs. For example, the arduous, repetitive science 
that led to the production of stabilized CdFabK enzyme and balanced assay conditions 
was an absolute prerequisite for the subsequent phenylimidazole CdFabK inhibitor 
validation and preliminary biochemical screening of virtual screening hits. A brief 
synopsis illustrating these very points is discussed below.  
 
 
Results and Discussion of Methods and Techniques Employed in This Work 
 
 
Target Identification and Production 
 
 Embarking on the investigation of arguably any novel and rational antibacterial 
drug target begins simply with a thorough analysis of the data at hand. Whether it is 
genomic data, microbiological data, or a basic literature search, the investigation of 
 
96 
rational antibacterial targets requires just what the name implies, “rationalization.” The 
work conducted herein marked the beginning of two different projects previously 
conceptualized by the principal investigator of the laboratory based off of rational 
navigation of literature and genomic data.  
 
As seen in Chapter 2, at the time of inception, the bacterial topoisomerase I 
project was undertaken based on the data available at the time, which indicated that 
streptococci possessed the gene responsible for topoisomerase I, topA, and lacked the 
gene responsible for topoisomerase III, topB. After this work had commenced, however, 
protein annotations had arisen that introduced at least some level of doubt in both 
directions. As the lab in which this work was carried out does not conduct actual bacterial 
genetics research, a substantial amount of bioinformatic analysis was invested into 
ascertaining whether or not streptococci do in fact possess the topB gene and, in turn, 
express topoisomerase III. This included genomic analyses, gene searches, protein 
searches, various BLAST searches, and various literature searches. At the time this work 
was written, this question still remained. 
 
Significant preliminary work has been conducted in order to further characterize 
and validate bacterial topoisomerase I, including the development of a simplified and 
rapid protocol for the high-yield production of pure and active full-length topoisomerase I 
from the gram-positive model organism, S. mutans. Different affinity, fusion, and 
solubility tags were utilized, as well as different expression systems and purification 
modalities. The effectiveness of the protocol results in substantial target production that 
can later be used for further investigational studies and, therefore, still represents a 
valuable contribution. Whether or not streptococci produce topoisomerase III, the ability 
to effectively produce the bacterial topoisomerase I target in bulk amounts opens up a 
variety of studies that can be carried out, including but not limited to bacterial 
topoisomerase I enzymology, assay development, compound screening, and further 
structural studies. As several other notable pathogens express topoisomerase I as their 
sole type IA topoisomerase, high-yield production of target SmTopoI not only permits 
the continued investigation of the respective enzyme, but also affords the opportunity to 
further characterize and validate the target and potentially translate the findings to those 
pathogens where it is more certain bacterial topoisomerase I will represent a narrow-
spectrum antibacterial drug target. Furthermore, as topoisomerases are traditionally such 
effective chemotherapeutic targets, the option of pursuing bacterial topoisomerase I as a 
broad-spectrum antibacterial drug target also still exists.  
 
With respect to the FabK project, effective collaborations ensued that answered 
genetic essentiality questions, highlighting the importance and benefit of such 
partnerships.67 Nonetheless, thorough bioinformatic analyses were also conducted with 
respect to the fabK gene and ongoing evaluations are being undertaken to survey the FAS 
II-related proteome of not only pathogenic bacteria, but also that of the ever-expanding 
bacteria that comprise the human microbiome.206-208 Such a continuous bioinformatic 
analysis has allowed for an ongoing and contemporaneous survey of the bacterial battle 
field, as it were, and in turn acts as a type of real-time reconnaissance of the effects FabK 




CdFabK enzyme target production evolved substantially throughout this work. 
Different affinity tag placements were combined with multiple purification techniques, 
along with systematic stability and activity studies in order to determine optimal salt, 
glycerol, and buffer and pH conditions. Ultimately, what was originally an inactive and 




Preliminary Target Characterization 
 
 Initial difficulty was met when attempting to produce and characterize SmTopoI. 
As stated earlier, the DNA-binding nature of the target introduced foundational 
difficulties with procuring stable enzyme. Stabilizing conditions were elucidated via 
implementation of the thermal shift assay, which indicated high salt and acidic stabilizing 
conditions for full-length SmTopoI. Simple target enzyme parameter analysis, coupled 
with in silico homology modeling and extensive literature searches led to rational 
shortened construct design that later resulted in highly diffracting SmTopoI_N65 protein 
crystals.209  
 
 As mentioned above, CdFabK stability and activity was optimized via systematic 
salt, glycerol, and buffer and pH trials utilizing biochemical assays. This eventually 
permitted further target characterization that ultimately furnished effective assay 
conditions for inhibitor screening. Additionally, optimization of CdFabK stability under 
prolonged dilution and exposure to DMSO was of particular significance as many recent 
studies have underscored the importance of screening under extended enzyme-compound 
incubation times in order to discover slow-binding inhibitors.210-213 
 
 
Compound Screening and Hit Selection 
 
 As previously discussed, an initial method for screening compounds is at times an 
intellectual one, first involving a thorough literature review in order to survey the 
chemical characteristics of any known potential inhibitors or chemical probes of interest. 
With respect to bacterial topoisomerase I, there is still no clinically marketed catalytic 
topoisomerase I inhibitor to date, nor is there a standard, specific bacterial topoisomerase 
I catalytic inhibitor reported in the literature for laboratory use. Regarding FabK, 
prototype phenylimidazole and benzothiazole compounds used in previous studies 
throughout the literature were found upon prior literature searches conducted by the 
principal investigator of the laboratory.163-166 These previously known SpFabK inhibitors 
served as the launching point for preliminary hit screening against CdFabK at 10 M as 
discussed earlier in this work. Moreover, these inhibitors and additional phenylimidazole 
analogues were similarly screened and hits were considered to be any compound that 






Target and Hit Validation and Characterization 
 
 From the attained SmTopoI_N65 crystals, the three-dimensional structure of 
SmTopoI_N65 was determined to 2.06 Å resolution, and structural characterization was 
able to be conducted. This in turn resulted in a number of findings that significantly 
added to the overall structural understanding and characterization of SmTopoI. This 
includes overall similarities and differences between SmTopoI and topoisomerase I 
homologues from other bacteria. Of particular note, these structural studies revealed a 
relatively unique active site-adjacent loop that may be worth assessing in greater detail in 
the future.  
 
 A thorough assessment of those phenylimidazole analogues and benzothiazoles 
that met the 50% CdFabK inhibition at 10 M hit identification threshold indeed led to 
further hit validation and IC50 knowledge that can be used in later lead optimization and 
structure-guided lead development. Furthermore, phenylimidazole inhibitor modality 
studies further validated the phenylimidazoles as CdFabK inhibitors and led to further 
inhibitor characterization. CdFabK enzymology studies led to apparent Km 
determinations for the NADH cofactor and Cro-CoA enoyl substrate, which in turn led to 
optimal balanced assay conditions. This will allow for more effective compound 
screening in the future as it will increase the chances of discovering both competitive and 
uncompetitive inhibitors. Additional hit characterization was carried out via selectivity 
analysis, which confirmed selective inhibition of FabK over an alternative bacterial enoyl 
reductase, FabI.  
 
 
Lead Development  
 
With respect to CdFabK inhibitors, the phenylimidazole analogue 1g showed 
noteworthy merit as it displayed potency slightly lower yet very similar to the 
phenylimidazole prototype 1b, but also showed increased solubility. Previous hit 
characterization allowed for the direct comparison of the IC50 values of the benzothiazole 
prototype, AG-205, against CdFabK and SpFabK. Such a comparison indeed had 
interesting and noteworthy implications. Namely, the medicinal chemistry modifications 
made to AG-205 to arrive at phenylimidazole 1b that led to substantially improved 
inhibitory potency against SpFabK (low micromolar to low nanomolar, respectively) 
does not appear to translate to increased potency against CdFabK.164,166 As such, a 
rational return to the original AG-205 benzothiazole scaffold was undertaken for an SAR 
reset to be conducted more thoroughly in the future for effective lead development. In the 
meantime, the alternative benzothiazole compound KH-70 recently exhibited the highest 
observed inhibitory potency against CdFabK at the time of this work, suggesting at least 








 The research presented here showcases the investigation of two very different 
narrow spectrum targets in antibacterial drug discovery. Both projects presented unique 
obstacles and successes and, therefore, required the implementation of various subjective 
techniques and methods. While various aspects of each project progressed to different 
stages, work remains regarding both projects.  
 
 
Bacterial Topoisomerase I Project 
 
Genomic analysis of streptococci 
 
The lingering uncertainty regarding whether or not streptococci possess the topB 
gene, and therefore whether or not streptococci indeed fit the original narrow spectrum 
hypothesis, represents a quandary that must be resolved. As such, determining whether or 
not streptococci possesses the topB gene and, therefore, whether or not they express 
topoisomerase III should be a top priority for future work. Further bioinformatic analyses 
would offer more information, but certainty is likely to only be found in benchtop 
bacterial genetic work. As such work is outside the scope of the principal investigator’s 
laboratory as it equipped at this time, a gifted collaborator with expertise in bacterial 
genetics and, possibly, a research emphasis on streptococci would be of significant worth 
to the future progress of this project. 
 
Full-length SmTopoI crystal structure 
 
 Useful insights were indeed gleaned from the determination of the three-
dimensional structure of the shortened 65-kDa amino terminal fragment of SmTopoI, 
SmTopoI_N65. However, as SmTopoI_N65 lacks the entire carboxy terminal domain, a 
full-length structure of SmTopoI would contribute substantial structural information that 
could potentially in turn be leveraged into effective structure-guided drug development 
efforts. As it was already exhaustively determined to be unlikely, or at the very least 
exceptionally difficult, to obtain full-length apo SmTopoI crystals, it is likely that co-
crystallography trials involving short oligonucleotide substrates with or without additive 
compounds would be of immediate benefit with respect to this particular aim. As SAR 
studies are an eventual long-term goal, this is a logical next step for this project. 
 
SmTopoI mutational studies 
 
 Knowledge gleaned from the determination of the SmTopoI_N65 crystal structure 
includes the relatively unique nine amino acid loop extension immediately adjacent to the 
active site. As this feature has not been discussed or elucidated any further in the 
literature, a deeper understanding may be warranted. In order to probe any significance of 
the loop, mutational studies could be undertaken to delete the loop and compare mutant 
SmTopoI to wild-type SmTopoI. Any changes in enzyme kinetics or nucleotide binding 
 
100 
specificity would be a significant discovery and, whether any notable change occurred or 
not, would further the understanding of the loop extension. Additionally, it may help 
ascertain whether or not the loop would be worth targeting or engaging for any future 
rational antibacterial drug discovery efforts.  
 
High throughput topoisomerase I assay development 
 
 Currently, the only well-validated assay for measuring the activity of bacterial 
topoisomerase I is an agarose gel-based DNA relaxation assay. This technique, while 
effective, is extremely low-throughput and is not immediately digitized for consistent 
comparisons. As such, an immediate need for successful antibacterial drug discovery 
efforts directed at topoisomerase I includes the development of a high throughput assay. 
This would allow for effective and efficient screening of large compound libraries as well 
as efficient enzymatic studies. As bacterial topoisomerase I acts independently of ATP 
and instead relies on the torsional strain of negatively supercoiled DNA, the only 
measurable entity for assaying is the actual extent of DNA supercoiling itself, which 
presents an inherently difficult task. Nonetheless, such a development would be a 








Though diffracting CdFabK protein crystals have been acquired, the optimal 
crystals thus far have only diffracted to roughly 3.5 Å. In order to serve any real utility in 
structure-guided drug discovery efforts, high quality crystals that diffract near 2.0 Å or 
better are necessary to analyze atomic level interactions and peptide sidechains. To this 
end, numerous crystallography methods have been attempted up to this point to no avail. 
Countless alternative crystallization methods remain to be tried, though, ranging from 
immediately accessible techniques to those that are more arduous and time consuming. 
Methods that could be attempted immediately include but are not limited to co-
crystallizing different additive screens, co-crystallization trials with newly found inhibitor 
like KH-70, producing the target enzyme in alternative buffers, increased purification 
steps to remove any remaining contaminant proteins that may be interfering with crystal 
packing and quality, and various digestion methods.214  
 
More time consuming and taxing methods should also be explored, include 
various target enzyme mutational or deletional studies for the purpose of construct 
optimization, including modifying solvent exposed hydrophobic or flexible peptide 
regions that may result in non-specific aggregation and compromise ordered crystal 
lattice formation and organization.215,216 To this end, the determination of the CdFabK 
structure from the current best diffracting crystals may only result in the discernment of 
overall structure, but it may also afford insight into the crystallographic unit cell and 
crystal packing modalities, which may help drive the rationalization strategy behind any 
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future mutational studies. While all of these options are worthwhile endeavors, for the 
mere sake of expediting the process, co-crystallography with newly discovered potent 
CdFabK inhibitors would likely be an ideal place to start the next phase of a 
crystallization campaign. 
 
Further hit validation and characterization 
 
 As the benzothiazole analogue KH-70 was an extremely recent hit, further hit 
validation and characterization need to be conducted. Similarly, additional SAR studies 
should be undertaken, focusing on benzothiazole analogue SAR by synthetic medicinal 




The optimized CdFabK assay conditions should be leveraged as practicably and 
aggressively as possible for the discovery of novel CdFabK inhibitors. Small in-house 
libraries can be immediately screened. Likewise, virtual screening campaigns have 
already commenced by others in the laboratory, and high-priority in silico hits can be 
screened and verified in vitro and further validated. The utility of discovering inhibitors 
with both novel and similar scaffolds would be substantial. Novel scaffolds would 
introduce a new SAR opportunity and help further characterize the CdFabK target, and 
analogues of known inhibitor scaffolds would further elucidate current SAR studies. 
Related to known scaffolds, analogues of current inhibitors could be searched for online 
as a time- and cost-effective means of conducting SAR by commerce, effectively 
furthering iterative lead development and SAR expansion on the phenylimidazole and 
benzothiazole compounds.217,218  
 
Orthogonal high throughput assay development 
 
 The current CdFabK assay methods involve monitoring the fluorescence or 
absorbance of NADH during the enzymatic reaction. As many small molecules found in 
various compound screening libraries are in fact fluorescent or colored, substantial 
amounts of false positives can arise when using fluorescent- or absorbance-based 
assays.219 An orthogonal assay capable of counter-screening and further validating any 
potential hits discovered upon initial fluorescence- or absorbance-based assays (or vice 
versa) would be of substantial value. Any such assay should possess a number of ideal 
characteristics. First, it should be orthogonal to fluorescence- and absorbance-based 
assays, as discussed, such as a chemiluminescent assay. It should also be plate-based in 
order to accommodate high throughput implementation. Additionally, the ability to be 
run in low-volume would be beneficial as it would decrease resource consumption and 
assist in the high throughput requirement. Low cost would be ideal, but not a necessity as 
high throughput screens are generally accepted as rather costly endeavors. And lastly, the 
assay should be capable of producing a significantly high screening window coefficient, 
or Z’ factor, under moderate controls in order to reliably report any discovered hits at the 







Despite the recent increase in the number of novel antibacterial agents in the 
pipeline, there is still a noticeably small number of agents that possess novel mechanisms 
of action, and an even more noticeable absence of small-molecule compounds directed at 
novel targets. In fact, the only antibacterial agent currently in the pipeline that is directed 
at a novel target is the anti-pseudomonal synthetic beta hairpin peptidomimetic known as 
murepavadin (POL7080, Polyphor, Ltd.) currently in late stage (Phase III) 
development.6,38 While absolutely a welcome contribution to the fight against 
antimicrobial resistance, murepavadin does not meet the criteria of being a “small 
molecule,” and instead falls into the category of novel biologic agents increasing in 
popularity across most areas of drug discovery.222 Again, while any novel antibacterial 
agent is desirable, including any biologic, the desirable benefits of small-molecule 
antibacterial agents should not be overlooked. This is especially the case when 
considering antibacterials. Due to their inherent purpose, antibacterial agents in particular 
need to exhibit significant stability, cost-effectiveness, and ease of widespread 
administration. Rationale for this is due in part to the necessity for antibacterial 
stockpiling, dispersal in potentially harsh climates where many major infectious diseases 
are focused, and the need for rapid response to outbreaks or bioterror events. In general, 
biologics are more expensive than small-molecule drugs, less stable, more likely to cause 
adverse immune responses, and more difficult to administer.223 These points, on top of 
the aforementioned fact that there are currently no novel small-molecule antibacterial 
agents with novel targets in the current antibacterial drug discovery pipeline, highlight 
the continuing and apparent need that still exists to fill this void.  
 
Obvious merit exists for the development of narrow-spectrum antibacterial agents, 
and calls for such are only gaining momentum.2,54 As discussed throughout this work, 
significant advantages are associated with narrow spectrum antibacterial agents—mainly 
the counter to the disadvantages seen with broad-spectrum antibacterial agents. In 
general, the major benefits of narrow-spectrum agents include an attenuation of microbial 
selection for wide-spread multidrug resistance pertaining not only to the pathogens 
necessitating pharmacotherapy, but also commensal bacteria capable of harboring and 
spreading resistance mechanisms, as well as the related mitigation of collateral damage to 
the human microbiome. Though narrow-spectrum antibacterial drug discovery appears to 
hold great potential value, it is not without significant price. As showcased in this work, a 
substantial amount of rationalization and investment—intellectual or otherwise—is 
required in the pursuit of narrow-spectrum targets in antibacterial drug discovery. This 
includes target identification and production, preliminary target characterization, 
compound screening and hit selection, further target and hit validation and 
characterization, iterative lead development, followed by continued narrow-spectrum 
activity and dysbiosis analyses on top of all of that. While indeed difficult, different 
research groups are coming up with innovative modalities of identifying and pursuing 
narrow-spectrum targets. Modern methods include targeting enzymes that are unique and 
essential to specific pathogens of interest (as seen in this work), pursuing bacteriocins and 
synthetic peptides that only target particular pathogens and, interestingly, a return to the 
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whole-cell phenotypic screening modalities reminiscent of those used throughout the 
golden era of antibacterial drug discovery.2,38,54,67 
 
After surveying the global issue of antibacterial resistance and the concerted 
efforts being undertaken to combat it, it is clear that a multi-faceted approach is required 
to effectively respond to this growing threat. As such, it would be inaccurate to argue that 
the only answer to the issues currently presented lies in narrow-spectrum antibacterials. 
Instead, it represents a single component of a plurality of different approaches needed. As 
long as infectious disease diagnostics are not instantaneous, broad-spectrum antibacterial 
agents will always be necessary for empiric therapy. In an ideal situation, after an 
accurate diagnosis is made, antibacterial de-escalation could be implemented and a 
patient could be transitioned to a narrow-spectrum antibacterial therapy, thereby 
effectively treating an infection and mitigating both the damage done to the patient’s 
microbiome, and mitigating the promotion of antibacterial drug resistance. For this ideal 
situation to occur, however, substantial progress still needs to be made toward the 
development of narrow-spectrum antibacterial agents, and such progress begins with 
earnest investment in the investigation of narrow-spectrum targets in antibacterial drug 
discovery. This work highlights such investment and, in turn, progress with respect to the 
investigation of both bacterial topoisomerase I and bacterial enoyl-acyl carrier protein 
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